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ABSTRACT 
Prostanoids (prostaglandins, prostacyclin, and thromboxane) play an important role in several 
physiological and pathological processes in the female reproductive organs. Cyclooxygenase 
(COX) enzymes are the rate-limiting enzymes in the conversion of arachidonic acid (AA) to 
prostanoids. COX-2, the inducible COX isoenzyme, is expressed at low levels in basal conditions, 
but is induced by cytokines, tumor promoters, and hormones. The aim of this study was to 
investigate COX-2 expression in gynecological organs during parturition and in ovarian carcinoma.  
 
Prostanoids are important mediators of human parturition at term and in preterm conditions. Fetal 
membranes have been previously shown to express elevated levels of COX-2 at the onset of labor. 
We investigated the expression of COX-2 in myometrial samples during parturition by Northern 
blot analysis, and observed a 15-fold elevation in COX-2 mRNA expression at the onset of labor. 
Cultured human myometrial cells expressed low levels of COX-2 mRNA in baseline condition, but 
stimulation of these cells with a proinflammatory cytokine interleukin-1β (IL-1β) caused a 17-fold 
induction of COX-2 mRNA expression. In addition, IL-1β induced expression of COX-2 protein, 
and thereafter the production of prostacyclin, which was blocked by a COX-2 selective inhibitor, 
NS-398. These data suggest that COX-2 is an important inducible prostanoid-producing enzyme in 
the myometrium during parturition. However, although selective COX-2 inhibitors may be effective 
in prevention of premature birth, their use is limited by fetal side-effects, such as oligohydramnions 
and constriction or premature closure of the fetal ductus arteriosus. 
 
Prostanoids have been connected to carcinogenesis because they can reduce apoptosis and host 
immune response and increase angiogenesis and invasion. Furthermore, the use of acetylsalicylic 
acid (ASA) and other nonsteroidal anti-inflammatory drugs is associated with the reduced risk of 
cancer-related deaths especially in the digestive tract. COX-2 is frequently expressed in human 
carcinomas, and inhibition of COX-2 suppresses tumor formation in various animal models of 
carcinogenesis. Importantly, COX-2 selective inhibitors have recently been found to reduce tumor 
burden in patients with familial adenomatous polyposis. In order to investigate the role of COX-2 in 
gynecological malignancies, the most lethal gynecological carcinoma, ovarian carcinoma, was 
studied. Serous and mucinous types of ovarian carcinoma were selected because of their different 
pathogenesis and outcome. COX-2 protein expression was investigated by immunohistochemistry 
in 442 serous and 56 mucinous ovarian carcinoma specimens. COX-2 immunoreactivity localized 
mainly to the epithelial cancer cells, but also in the stromal compartment of the tumor, especially in 
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the mucinous carcinomas. COX-2 expression was elevated in the epithelial cancer cells more often 
in the serous (70%) than in the mucinous (39%) tumors (P<0.0001). Elevated epithelial expression 
of COX-2 associated with high histological grade in both histologies (P<0.0001 in serous and 
P=0.0285 in mucinous) and with reduced survival in serous carcinoma (P=0.0011). When COX-2 
expression was compared to other molecular markers related to carcinogenesis of serous ovarian 
tumors, it was found to correlate with altered expression of tumor suppressors p53 and SMAD4, and 
with amplification of the HER-2 oncogene. Furthermore, cytoplasmic expression of the mRNA 
stability factor HuR correlated with epithelial COX-2 expression in both histologies, and was 
associated with reduced survival in serous ovarian tumors. Thus, HuR is the first mRNA stability 
protein, the expression of which has been linked to reduced survival in carcinoma patients. This 
property of HuR may in part depend on its ability to induce COX-2 expression. We have observed 
that inhibition of HuR by use of small interfering RNA (siRNA) technology reduced COX-2 
expression in serous ovarian carcinoma cells under tissue culture conditions.  
 
In conclusion, our study suggests that expression of COX-2 plays an important role in the synthesis 
of prostanoids during parturition in the myometrium. In serous ovarian carcinoma, elevated COX-2 
expression is associated with reduced survival, which may indicate that COX-2 selective inhibitors 
might prove to be effective in the treatment of this malignancy. However, clinical trials are needed 
to test the safety and efficacy of COX-2 inhibitors in these diseases.    
 10
REVIEW OF THE LITERATURE 
1. COX ENZYMES 
1.1. Synthesis of prostanoids 
Prostanoids such as prostaglandins (PGs), prostacyclin (PGI2), and tromboxanes (Txs) are 20-
carbon polyunsaturated fatty acids synthesized from AA. AA is liberated from membrane 
phospholipids by phospolipase A2 (PLA2) and to some extent by PLC (Smith and Marnett 1991). 
Cyclooxygenase is an enzyme, the COX activity of which catalyzes the conversion of AA to PGG2 
by introducing two molecules of O2 into AA, and the peroxidase activity then reduces PGG2 to 
PGH2, which is further converted into various biologically active prostanoids such as PGE2, PGF2α, 
PGD2, PGI2 and TxA2 by tissue-specific synthases (Dempke et al. 2001) (Fig.1). 
 
 
Figure 1. The prostanoid biosynthetic pathway. COX=cyclooxygenase; NSAIDs=non-steroidal 
anti-inflammatory drugs, COXIBs=COX inhibitors. 
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Prostanoids are short-lived and act as local hormones in an autocrine or paracrine manner. They act 
through seven transmembrane receptors which belong to the G protein-linked receptor family, or 
through the nuclear peroxisome proliferator-activated receptors (PPARs) (Dussault and Forman 
2000, Sugimoto et al. 2000). Prostanoids have many physiological functions such as regulation of 
platelet aggregation, cytoprotection of the stomach, regulation of kidney perfusion, reproduction, 
and parturition. In addition, their biosynthesis is related to inflammation and carcinogenesis as well 
(Smith and Langenbach 2001).  
 
1.2. COX enzymes 
Two COX genes have been cloned, COX-1 and COX-2. COX-1 complementary deoxyribonucleic 
acid (cDNA) was originally cloned from sheep seminal vesicles (DeWitt and Smith 1988, Merlie et 
al. 1988, Yokoyama et al. 1988) and the human homolog was characterized in 1991 from platelets 
(Funk et al. 1991). COX-2 cDNA was first cloned from chicken embryo fibroblasts in the late 80s 
(Simmons et al. 1989), and its murine homolog was identified as a tumor promoter- and serum-
inducible immediate early gene product from Swiss 3T3 fibroblasts (Kujubu et al. 1991) and from 
C127 fibroblasts (O'Banion et al. 1992). Human COX-2 cDNA was originally cloned from human 
umbilical vein endothelial cells by Hla and Neilson (1992). COX enzymes are composed of three 
domains: an epidermal-growth factor-like domain, a membrane-binding region, and a large catalytic 
domain. The catalytic domain contains both cyclooxygenase and peroxidase activity sites (Luong et 
al. 1996). The size of the human COX-1 gene is larger than the human COX-2 gene mainly due to 
the different sizes of the introns. Most of the exons are conserved between COX-1 and -2, with the 
exception of the absence of exon 2 in COX-2. The COX-2 mRNA is approximately 4.5 kb, and the 
COX-1 mRNA is 2.7 kb (Williams and DuBois 1996). Recently, Chandrasekharan et al. (2002) 
identified from canine cerebral cortex COX-3 and PCOX-1α, which are formed from the COX-1 
gene by alternative splicing. COX-3 may be the target of acetaminophen, also known as 
paracetamol, which is an antipyretic and analgesic drug with very weak anti-inflammatory activity 
(Chandrasekharan et al. 2002). Table 1 depicts the basic characteristics of COX-1 and COX-2 
genes. 
 
The promoter region of the COX-1 gene contains no TATA box but possesses high GC content, 
which is a characteristic of a housekeeping gene (Wang et al. 1993). The COX-2 promoter region 
contains a TATA box and a number of transcriptional regulatory sequences including nuclear factor 
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(NF) -κB, the NF-IL-6, and the cyclic AMP response element (CRE). The COX-2 gene has an 
extensive 3´-untranslated region (UTR) having several AU-rich elements (AREs), which have been 
associated with rapid degradation of the transcript (Appleby et al. 1994). No differences exist in the 
subcellular location of COX-1 and -2, and they are both expressed in endoplasmic reticulum and 
nuclear envelope (Morita et al. 1995, Spencer et al. 1998). 
 
Table 1: Comparison of COX-1 and COX-2 genes and gene products. 
 
Parameter COX-1 COX-2 
Human chromosome Chromosome 9 Chromosome 1 
Gene size 22 kb 8.3 kb 
TATA box No Yes 
Promoter GC rich NF-κB, NF-IL-6, CRE 
Regulation Constitutive Inducible 
mRNA size 2.7 kb 4.5 kb 
Molecular mass 72 kDa 72 kDa 
Protein localization Endoplasmic reticulum 
and nuclear envelope 
Endoplasmic reticulum 
and nuclear envelope 
 
 
1.3. Function of COX-1 and COX-2 
Although COX-1 and COX-2 are enzymatically quite similar isoenzymes, regulation of gene 
expression differs drastically. Whereas COX-1 is constitutively expressed in most tissues and the 
expression of COX-1 is usually not regulated, COX-2 expression is low or non-detectable in most 
tissues but can be readily induced by hormones, cytokines, growth factors, and tumor promoters, 
e.g., phorbol 12-myristate 13-acetate (PMA). For this reason, it is thought that COX-1 controls 
normal physiological functions such as cytoprotection of the gastric mucosa, platelet aggregation, 
and vasodilatation in the kidney, whereas the function of COX-2 has been associated with 
inflammation and carcinogenesis (Needleman and Isakson 1997). Inhibition of COX-2 is thus 
thought to mediate the great majority of the anti-inflammatory properties of NSAIDs. However, 
recent studies suggest that COX-2 may also play an important role in various physiological 
processes such as regulation of renal medullary blood supply, salt excretion, and systemic blood 
pressure (Harris and Breyer 2001). COX-2 is also important in reproductive functions, since it is 
involved in ovulation, implantation, and in the angiogenesis needed for establishment of the 
placenta. Animal studies have suggested that both COX enzymes are expressed in the ductus, with 
COX-1 preceding COX-2 in the course of gestation (Guerguerian et al. 1998, Coceani et al. 2001). 
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Hence, both COX-1 and -2 have been implicated in PGE2 formation in fetal ductus at term, while 
COX-1 has been assigned a predominant role in the premature fetus. COX-2 is essential for 
initiation of the closure of the ductus arteriosus at term (Hinz and Brune 2002).In the mouse ductus, 
the PGE2 synthesis comprises both COX-1 and -2. When the function of COX is suppressed, the 
production of vasodilator nitric oxide (NO) is upregulated. PGE2 and NO can function 
synergistically in keeping the ductus patent (Baragatti et al. 2003).  
 
Many factors associated with inflammation have been shown to induce COX-2: These factors 
include bacterial lipopolysaccharide (LPS) and also cytokines such as IL-1 and tumor necrosis 
factor (TNF)-α (Vane et al. 1998). Human and animal models of inflammatory arthritis strongly 
suggest that increased expression of COX-2 is responsible for the increased production of PGs 
found in inflamed joint tissues (Anderson et al. 1996, Amin et al. 1997, Crofford et al. 1994). In 
carcinogenesis, many effects of COX-2 can be facilitated by either PGE2 or PGF2α, including 
stimulation of proliferation, inhibition of apoptosis, enhanced production of matrix 
metalloproteinases, promotion of angiogenesis, and induction of immunosuppression. COX-2-
derived prostanoids can suppress apoptosis by upregulating anti-apoptotic Bcl-2 (Sheng et al. 
1998). COX-2 also contributes to the production of pro-angiogenic factors, including vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), since treatment of 
COX-2-overexpressing colorectal cancer cells with a COX-2 selective inhibitor, NS-398, 
diminished secretion of these factors (Tsujii et al. 1998). Furthermore, in a rat corneal model, 
bFGF-induced blood vessel formation was suppressed by another COX-2 selective inhibitor, 
celecoxib, but not by a COX-1 selective inhibitor, SC-560 (Masferrer et al. 2000). COX-2 can also 
modulate invasive properties of human cancer cells (Tsujii et al. 1997), for instance by upregulating 
the expression of CD44, which leads to increased invasiveness of tumor cells (Dohadwala et al. 
2001) and increases immunosuppression by inhibiting T and B cell proliferation, cytokine synthesis 
and diminishing the activity of natural killer (NK) cells (Rhind et al. 1999). All this suggests that 
COX-2 affects multiple steps of carcinogenesis and that its inhibition could be an effective modality 
in treatment of cancer patients. 
 
1.4. Gene-deletion studies of COX enzymes 
Cox-1 and -2 knockout mice were generated in the mid 90s (Langenbach et al. 1995, Morham et al. 
1995). Cox-1-deficient mice showed reduced inflammatory response to AA, and their platelet 
aggregation was impaired. Homozygous female mice produced litters of normal size, but they had 
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delayed parturition, and thereafter most of the pups were born dead or died shortly after birth 
(Langenbach et al. 1995). However, the Cox-1-deficient mice which survived were generally quite 
healthy. They did not have spontaneous stomach ulcers, and they showed less indomethacin-
induced gastric ulceration, although Cox-1 is thought to be responsible for production of 
cytoprotective PGs .  
 
In contrast to Cox-1-deficient mice, genetic deletion of the Cox-2 gene caused abnormalities more 
severe. Most homozygous mutant animals died at approximately 8 weeks after birth, due to 
abnormalities in their kidneys. Kidneys from newborn homozygous mice were normal, but those of 
8-week-old homozygous mutant mice were small and pale. The number of glomeruli was reduced 
below that of wild-type kidneys. Hence, the renal pathology of Cox-2-deficient mice was 
considered to be due to defective postnatal development of the glomeruli (Dinchuk et al. 1995, 
Morham et al. 1995). Another neonatal event in Cox-2-deficient mice was defective closure of the 
ductus arteriosus. Although the ductus showed normal closure in Cox-1 null mice, about 35% of 
Cox-2 null mice died with a patent ductus within 48 hours after birth. However, the fact that 65% of 
Cox-2-null mice survived to weaning suggests that Cox-1 can play a compensatory role (Loftin et 
al. 2001). 
 
The genetic disruption of Cox-2 produced multiple failures in female reproductive processes. Cox-2 
knockout females were largely infertile due to ovulation failure. Their ovaries were small, owing to 
a virtual absence of the corpora lutea, but ovarian follicular development was apparently normal 
(Dinchuk et al. 1995). In addition, their implantation and decidualization processes were defective 
(Langenbach et al. 1995, Lim et al. 1997). Lim et al. (1997) found that in homozygous Cox-2 
knockout female mice, the principal early reproductive defect involved uterine receptivity to 
implantation. This finding was demonstrated by transplanting wild type (Cox-2 +/+) murine 
blastocysts into homozygous mutant Cox-2-deficient pseudopregnant mice. In recipient mothers, 
blastocyst implantation was impaired, a defect which could not be reversed by injection of 
progesterone.  The Cox-2 selective inhibitor Dup697 could prevent implantation also in wild type 
and heterozygous (Cox-2 -/+) mice. These results indicate that the uterine epithelium of 
homozygous Cox-2 mutant mice is largely responsible for the implantation failure. Lim et al. (1997) 
showed that a stable analog of PGI2 could restore the decidualization of Cox-2-deficient mice, and 
thereafter showed the importance of PGI2 and inducible prostaglandin synthesis in early stages of 
implantation. 
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Compensatory Cox expression may, at least in part, explain why Cox-deficient mice are able to 
survive as well as they do (Kirtikara et al. 1998). However, these experimental observations on 
Cox-deficient mice clearly indicate that the original hypothesis that Cox-1 is involved in 
homeostatic functions, while expression of Cox-2 modulates inflammatory reactions, is too simple. 
It appears more likely that Cox-1 and -2 have distinct as well as overlapping actions in maintaining 
homeostasis in mice. 
 
1.5. Regulation of COX-2 mRNA stability 
COX-2 gene expression is regulated at both transcriptional and post-transcriptional levels 
(Ristimäki et al. 1994, Hla et al. 1999, Smith et al. 2000). In eukaryotic cells, the half-life of 
mRNA can vary from 20 minutes to 24 hours (Ross et al. 1995) and thus regulation of mRNA 
stability is an important component of gene expression (Chen and Shyu 1995, Brennan and Steiz 
2001). This is especially evident for short-lived transcripts, including certain proto-oncogenes, 
cytokines, and cytokine-response-genes that are inherently unstable. These genes are usually 
transcribed in a rapid but transient manner. This combination of regulatory steps of gene expression 
facilitates tight control over these potentially harmful proinflammatory and transforming factors. 
Degradation of mRNA can be regulated by specific cis-elements and trans-acting factors. The best-
studied cis-element is the adenylate- and uridylate-rich (AU-rich) element (ARE) found in the 
3'untranslated regions (UTRs) of many unstable mammalian mRNAs (Chen and Shyu 1995). An 
AU-rich consensus sequence was first observed in the 3'UTR of murine and human TNF-α mRNAs 
as well as in the mRNAs encoding human lymphotoxin (TNF-β), colony- stimulating factor (CSF), 
human and mouse IL-1, and human and rat fibronectin (Caput et al. 1986). Comparison of the ARE 
sequences of many oncogene and cytokine mRNAs led to the identification of motifs often present 
in multiple copies within the 3'UTR and constituting an AU-rich stretch of 50 to 150 nucleotides. 
When these AUUUA motifs are present within a functional ARE, they have a destabilizing role 
(Akashi et al. 1994; Chen et al. 1994). AREs are also potent stimulators of both decapping and 
deadenylation processes (Xu et al. 1997, Gao et al. 2001). AREs differ considerably in size, AU 
content, and number of AUUUA motifs. Databases have been developed which contain eucaryotic 
mRNA UTR sequences and specific regulatory signals. 
  
Trans-acting factors are RNA-binding proteins that selectively bind to mRNA’s 3’UTRs AU-rich 
areas. Several ARE-binding proteins have been identified. The Hu family of proteins are a group of 
RNA-binding proteins related to embryonic lethal abnormal vision (ELAV) proteins, essential in 
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Drosophila for neuronal development (Campos et al. 1985). Hu proteins have been shown to 
stabilize or to activate translation of target mRNA or both. The Hu family consists of three 
members that are neuronal tissue-specific: Hel-N1 (also known as HuB), HuC, and HuD. HuR (or 
HuA) is a Hu family member which is ubiquitously expressed (Ma et al. 1996). Other proteins 
capable of binding ARE are heat shock protein 70, nuclear ribonucleic proteins  (nRNP) like human 
nRNP (hnRNP) A1, hnRNP C, and hnRNP D, also known as AUF-1 (Brewer 1991), RNA-binding 
proteins with enzymatic activity, such as glyseraldehyde-3-phosphate dehydrogenase (GAPDH), 
and AUH. HuR is the best-characterized ARE-binding protein (Brennan and Steiz 2001). It is 
predominantly expressed in the nucleus, but has been shown to shuttle between nucleus and 
cytoplasm (Fan and Steiz 1998). HuR binds to ARE-containing mRNAs in the nucleus, and this 
complex is then transported to the cytoplasm. In the cytoplasm, mRNAs are released to the 
translational apparatus or released for rapid degradation (Gao and Keene 1996), after which HuR 
returns to the nucleus or degrades. Use of cell-permeable peptides has allowed identification of two 
distinct nucleocytoplasmic export mechanisms for c-fos mRNA (Gallouzi and Steiz 2001). One of 
these export proteins is the export receptor chromosome maintenance region 1 (CRM1), which 
binds to leucine-rich nuclear export signals present in two protein ligands of HuR: pp32 and 
APRIL. Shuttling of pp32 and APRIL is totally blocked by inhibition of CRM1 with a fungal 
metabolite called leptomycin B (LMB). LMB can cause G1 cycle arrest in mammalian cells and is a 
potent anti-tumor agent against experimental tumors in mice (Yoshida et al. 1990, Komiyama et al. 
1985). However, LMB has been shown to cause toxic side-effects in phase I trials for treatment of 
cancer (Kau and Silver 2003). In the case of RNA export, CRM1 binds to ribonuclear proteins 
containing a nuclear export sequence (NES). CRM1 inhibition produced an increased association of 
HuR with pp32 and with APRIL, and an increase in HuR ability to bind nuclear poly(A)+RNA in 
vivo. LMB inhibits the stabilization of COX-2 mRNA in human mammary cancer cells and 
suppresses IL-1β-induced COX-2 expression in human colon cancer cells and umbilical vein 
endothelial cells (Jang et al. 2003). 
 
HuR is known to stabilize several inducible mRNAs such as c-fos and TNF-α (Ma et al. 1997) and 
recently it was demonstrated that COX-2 mRNA contains HuR-binding AREs in its 3’UTR (Nabors 
et al. 2001, Dixon et al. 2001, Sengupta et al. 2003, Subbaramaiah et al. 2003, Cok et al. 2003). 
Consistent with its function as an mRNA stability protein, overexpression of HuR led to increased 
COX-2 expression in colorectal cancer cells (Dixon et al. 2001) and the down-regulation of HuR 
inhibited COX-2 expression in breast cancer cells (Sengupta et al. 2003). IL-1β was the first agent 
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shown to increase the half-life of the COX-2 transcript (Ristimäki et al. 1994), and recently IL-
1β was shown to increase the cytosolic content of HuR protein/COX-2 mRNA complexes (Cok et 
al. 2003). Previously, two staining patterns of HuR have been observed in human tumors: nuclear 
and cytoplasmic. There are no studies in which expression of HuR would have been connected with 
any clinical parameters in human tumors. 
 
2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) 
2.1. Mechanism of NSAIDs 
Reduction in prostanoid production by inhibition of COX enzymes appears to be the main 
mechanism of most NSAIDs. These drugs compete with AA for binding to the active site of the 
COX enzyme but do not inhibit the peroxidase activity (Smith and Marnett 1991). The classical 
NSAIDs, such as ASA, are nonselective, inhibiting both COX-1 and -2. Acetylation of serine 530 in 
COX-1 and serine 516 in COX-2 by ASA causes an irreversible inactivation of the COX enzymes 
(O'Banion et al. 1992). The substrate-binding site in COX-2 is larger and has a slightly different 
shape than that of COX-1. This allows the COX-2 selective inhibitors access to a side pocket 
located off the main substrate-binding site (Luong et al. 1996). Inhibition of COX-1 is thought to 
cause undesirable gastric adverse effects such as ulcers and reduction in renal blood flow. The 
analgetic, anti-pyretic, and anti-inflammatory effects of NSAIDs are thought to follow the inhibition 
of COX-2 activity. However, in rats, neither the COX-1 selective inhibitor SC-560 nor the COX-2 
selective inhibitor celecoxib sufficed to induce ulcers, but gastric damage occurred when these two 
inhibitors were administered in combination, suggesting that inhibition of both COX-1 and COX-2 
is required for NSAID-induced gastric injury (Wallace et al. 2000). In the platelet, the only 
detectable isoform is COX-1, and reduced platelet aggregation is not only a well-established 
adverse effect of ASA, but also the therapeutic tool against thromboembolic diseases (Vane et al. 
1998). 
 
Celecoxib is selective for COX-2, but at high concentrations it also affects COX-1 activity 
(McAdam et al. 1999). Selective COX-2 inhibitors, rofecoxib (Langman et al. 1999) and celecoxib 
(Emery et al. 1999), cause fewer gastrointestinal side-effects than do nonselective NSAIDs. These 
kinds of results has been observed also in clinical trials in which selective COX-2 inhibitors, 
celecoxib, rofecoxib, valdecoxib, and lumiracoxib have been approved for use by the US Food and 
Drug Administration. In the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial (Bombardier 
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et al. 2000), in the Celecoxib Long-Term Arthritis Safety Study (CLASS) (Fizgerald and Patrono 
2001, Fizgerald 2003), and in the Therapeutic Arthritis Research and Gastrointestinal Event Trial 
(TARGET) (Schnizer et al. 2004, Farkouh et al. 2004) the incidence of serious gastrointestinal 
events was reduced significantly in patients receiving coxibs in comparison with traditional 
NSAIDs. However, according to the recent Adenomatous Polyp Prevention on Vioxx (APPROVe) 
study, rofecoxib led to an increased risk for thromboembolic events that can cause myocardial 
infarction and stroke (Merck announcement 2004). The main mechanism behind this event is the 
depression of PGI2 production while the production of Tx remains stable, which can elevate blood 
pressure by increasing vasoconstriction and induce thrombotic events by enhancing the aggregation 
of platelets (Fizgerald 2004). The higher a patient’s intrinsic risk for cardiovascular disease, the 
more likely that these events may cause myocardial infarction and stroke.   
 
2.2. NSAIDs in benign gynecologic and obstetric processes 
High concentrations of prostanoids have been observed during normal menstruation, but especially 
in connection with menorrhagia (Ylikorkala 1994), dysmenorrhea (Bieglmayer et al. 1995), and 
endometriosis (Karck et al. 1996, Garzetti et al. 1998), all of which directly correlate with painful 
menstruation (Koike et al. 1992). COX activity has been implicated in the pathogenesis of 
polycystic ovary syndrome. Polycystic ovaries release greater amounts of PG than do normal 
ovaries (Navarra et al. 1996). Elevated levels of PGs have also been connected with infection and 
inflammation as a consequence of high levels of cytokines. In all these states, COX-2-selective 
inhibitors are at least as effective in pain relief and reduction of inflammatory reactions as are 
conventional NSAIDs, but offer a better gastrointestinal safety profile. Use of NSAIDs in women 
attempting to become pregnant has been associated with reversible female infertility (Smith et al. 
1996, Akil et al. 1996, Mendonca 2000, Norman 2001, Norman and Wu 2004). The use of selective 
or non-selective COX-inhibitors may cause luteinized unruptured follicle syndrome, a condition 
characterized by the ability of a normally growing preovulatory follicle to luteinize, but not rupture, 
in response to the luteinizing hormone (LH) surge. This results in entrapment of the oocyte and in 
infertile cycles. This syndrome has developed also after use of COX-2 selective inhibitor rofecoxib 
in normal daily amounts during the ovulation period (Pall et al. 2001). NSAIDs have served as 
tocolytic agents, among beta-2 agonists, calcium-channel inhibitors, and oxytocin antagonists. 
However, dose-dependent fetal side-effects limit their use. Oligohydramnions and constriction or 
premature closure of the fetal ductus arteriosus are frequent with traditional NSAIDs, but also occur 
after short-term use of the COX-2 selective inhibitor nimesulide (Sawdy et al. 2003a). These side-
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effects might be diminished by reduction in the dose of nimesulide without reduction in 
effectiveness (Sawdy et al. 2003b). After long-term use of nimesulide, no constriction of fetal 
ductus arteriosus could be observed in one study (Sawdy et al. 2004). It has been shown that 
tocolytic effects may be due to COX-2 inhibition, whereas fetal side-effects may be due to COX-1 
inhibition (Sawdy et al. 1997, Yousif and Thulesius 1998). 
 
2.3. NSAIDs and cancer  
Record-linkage studies have shown a lower incidence of gastrointestinal cancers among patients 
with rheumatoid arthritis, and use of NSAIDs was suggested to be responsible for this phenomenon 
(Laakso et al. 1986, Gridley et al. 1993). Consistent with these early observations, several 
epidemiological studies have shown an association between prolonged use of ASA and reduced risk 
for colon cancer (Thun 1994). Furthermore, the nonselective NSAID sulindac and the COX-2 
selective inhibitor celecoxib have reduced polyp burden in familial adenomatous polyposis (FAP) 
patients (Giardiello et al. 1993, Steinbach et al. 2000, Phillips et al. 2002). Clearly, NSAIDs have 
the potential to suppress carcinogenesis in the large bowel. Use of ASA has been associated with 
reduced incidence of cancer in the stomach and esophagus (Coogan et al. 2000; Farrow et al. 1998), 
and in the lung and breast (Harris et al. 1996; Schreinemachers and Everson, 1994).  
 
In ovarian cancer, regular use (three or more times per week for at least 6 months) of ASA was 
observed to associate with a reduced risk, after adjustment for age at menarche, parity, oral 
contraceptive use, and family history of first-degree breast cancer (Akhmedkhanov et al. 2001). 
However, in case-control studies, acetaminophen was the only NSAID significantly associated with 
reduced risk for ovarian cancer (Cramer et al. 1998, Rosenberg et al. 2000, Moysich et al. 2001), 
and the difference was most significant with the greatest frequency of use (Cramer et al. 1998, 
Moysich et al. 2001) and the longest duration (Rosenberg et al. 2000, Moysich et al. 2001). In 
cohort studies (Rodriguez et al. 1998, Fairfield et al. 2002, Sorensen et al. 2003), use of ASA, 
acetaminophen, or other NSAIDs has been inversely associated with ovarian carcinoma, and there 
was direct association of duration of use with cancer risk (Sorensen et al. 2003). There have also 
been studies reporting no association of ovarian cancer risk with NSAIDs (Tavani et al. 2000, Friis 
et al. 2002, Meier et al. 2002, Lacey et al. 2004). Acetaminophen is a poor COX inhibitor, it has 
only weak anti-inflammatory activity, and it has not been demonstrated to have any protective 
effect against colorectal carcinoma. It has, however, an antigonadotropic effect, which may explain 
the reduction in risk for ovarian cancer after its long use (Cramer et al. 1998).  
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There exist no studies on association of selective COX-2 inhibitors with risk for ovarian cancer. In 
vitro, the selective COX-2 inhibitor NS-398 inhibited production of PGE2 and proliferation of an 
ovarian carcinoma cell line (Rodriguez-Burford et al. 2002, Denkert et al. 2003). The cell 
proliferation was inhibited at concentrations of 50 to 500 µM, which are above the concentrations 
needed for inhibition of PGE2 production and which are 10 to 100 times as high as circulating levels 
of the drug during in vivo administration (Denkert et al. 2003). Furthermore, that inhibition of cell 
proliferation could not be reversed by addition of exogenous PGE2 suggests that NS-398 can reduce 
ovarian cancer cell proliferation, but the effect is independent of COX-2. The significance of this 
finding is unclear, due to the relatively high dose used in this in vitro setting. To this end, it is 
uncertain whether the use of NSAIDs or COX-2 selective drugs can act as chemopreventive agents 
in women at high risk for ovarian cancer. On the other hand, since COX-2 selective inhibitors are 
tested as neoadjuvant and adjuvant treatment modalities in various types of cancer, it would be 
important to know the extent of COX-2 expression also in ovarian carcinoma and whether it 
correlates with clinical parameters including survival. 
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3. COX-2 DURING PHYSIOLOGICAL GYNECOLOGICAL CONDITIONS 
3.1. COX-2 during the menstrual cycle  
The relationship between PG biosynthesis and ovulation was first observed during the early 70's 
(Armstrong 1981). Indomethacin-dependent inhibition of ovulation was initially reported in rats and 
rabbits (Armstrong and Grinwich 1972), but was subsequently observed in numerous animal 
species and humans (Armstrong 1981). The relationship between PGs and ovulation was further 
strengthened by investigations in which PGs were able to restore ovulation in indomethacin-treated 
animals (Tsafriri et al. 1973). By immunohistochemical methods, COX-2 expression has been 
discovered in the granulosa cell layer of human secondary and developing follicles (Tokuyama et 
al. 2003) and the corpus luteum (Matsumoto et al. 2001b), but not in primary or Graafian follicles 
(Matsumoto et al. 2001b, Tokuyama et al. 2003), in corpus albicans or the stromal cell layer of the 
ovary  (Matsumoto et al. 2001b), in normal ovarian surface epithelium (Matsumoto et al. 2001b, 
Denkert et al. 2002, Li et al. 2004, Shigemasa et al. 2003) or in the epithelial cells of inclusion 
cysts (Matsumoto et al. 2001b, Shigemasa et al. 2003). Cox-2 induction appears immediately after 
the LH surge in mice (Richards 1995). The time between surge and induction of COX-2 varies 
between animal species and affects the length of the ovulatory process (Richards 1997). Studies on 
the regulation of COX-2 in human pre-ovulatory follicles have been limited. However, the COX-2 
transcript in granulosa cells and the COX-2 protein in preovulatory follicular fluid have been 
detected in women enrolled in in vitro fertilization programs (Narko et al. 1997, Tokuyama et al. 
2001, 2003). In primates, COX-2 protein and intrafollicular PG levels can be observed 24 and 36 
hours after human chorionic gonadotropin (hCG) injection, which mimics the endogenous LH 
surge, and COX-2 mRNA as early as 12 hours post-hCG treatment in both granulosa and theca cell 
layers (Duffy and Stouffer 2001). This COX-2 induction accompanies normal oocyte development 
and seems to be necessary to produce the proteolytic enzymes that rupture the follicles (Tsafriri 
1995). COX-2-negative follicles were not luteinized and contained a compact cumulus-oocyte 
complex, suggesting an apparent failure to respond to the gonadotropin pre-ovulatory signal (Liu 
and Sirois 1998). The inductive trigger for increased COX-2 expression during ovulation may 
involve LH, follicle-stimulating hormone (FSH), transforming growth factor-α (Li et al. 1996), 
and/or IL-1β  (Narko et al. 1997). In addition, oocyte-derived factors enhance PG synthesis during 
the ovulatory process (Elvin et al. 1999), and PGs act as inducers of COX-2 expression in luteal 
cells (Nakamura and Sakamoto 2001, Tsai and Wiltbank 2001).  
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In human endometrium during the normal menstrual cycle, COX-2 is mainly localized to the 
perivascular cells and in the basal cell layer of proliferative glandular endometrium, but not in 
secretory phase glandular endometrium (Marions and Gemzell 1999, Uotila et al. 2002). The 
expression of COX-2 increases premenstrually (Jones et al. 1997), but no COX-2 expression is 
found in endometrium of postmenopausal women after two years’ use of continuous combined 
hormone replacement therapy (Hsu et al. 2003).  
 
Analysis of COX-2 expression in the cervix uteri of rodents and primates suggests that normally 
COX-2 is absent or only weakly expressed in the cervix during the normal menstrual cycle but 
increases during labor and parturition (Dong et al. 1996, Wu et al. 2000). In humans, although no 
immunoreactive COX-2 protein has been detectable in the histologically normal cervix (Kulkarni 
2001, Sales 2001), Landen et al. (2003) could find positive COX-2 expression in 50% of human 
papillomavirus infected cervix samples. 
 
3.2. COX-2 during pregnancy 
During pregnancy the uterine myometrium relaxes and accomodates the growing fetus. However, 
when labor commences, the uterine myometrium have to contract cyclically to give birth to the 
fetus. The quiescence of pregnant uterus is depending on the critical balance of oxytocin and its 
receptors (Zeeman et al. 1997), steroid hormones progesterone and estrogen (Zervou et al. 2002), 
gap-junction protein connexin (Chow et al. 1994) and synthesis of PGs and its receptors (Challis et 
al. 1997). Increased prostaglandin synthesis is thought to play a key role in the onset of labor and 
progress of parturition.  
 
Synthesis of PGs is suppressed in the ovary and in the endometrium after ovulation (Smith et al. 
1996), but it is increased again during the implantation period, which is an inflammatory-like 
reaction important for the increase in endometrial vascular permeability.  When progesterone levels 
are maximal (i.e., during pregnancy), basal PG production falls (Maathuis 1978). In the human 
endometrium, PG synthesis and COX-2 are up-regulated by gonadotropins at the time of decidua 
formation (Han et al 1999) and with the start of pregnancy in the luminal epithelium and the 
perivascular cells of human endometrium (Marions and Gemzell 1999). In animals, COX-2 
expression occurs in the stromal cells of endometrium at the site of implantation (Kim et al. 1999, 
Chakraborty et al. 1996, Charpigny et al. 1997). In mice, Gross et al. (1998) found Cox-1 to be 
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important for normal entry into parturition and that its absence led to peripartal fetal death; Cox-2 
could not compensate for the loss of Cox-1, thus supporting the role of Cox-1 in early stages of 
labor in this model. They also showed, however, that their pregnant knockout mice with the Cox-1 
and oxytocin null mutation had a normal onset of labor, although duration of labor was much longer 
than in wild type mice (Gross et al.1998). This indicates that Cox-1 may play some role in 
parturition. Because the Cox-1 has not been shown to be an inducible enzyme in this system, it may 
mediate the initial stages of labor onset, and when it undergoes suicide inactivation, the inducible 
Cox-2 may assume most of the responsibility for sustaining myometrial contractility and cervical 
ripening.  
 
The fetal membranes are thought to be the main source of PGs within the human uterus during 
parturition, and with labor a large increase occurs in production of PGs in fetal membranes (Skinner 
and Challis 1985). This increase in PG synthesis is thought to be due to induction of COX-2 
expression in the fetal membranes (amnion, chorion, deciduas), while COX-1 expression levels 
remain constant (Teixeira et al. 1994, Hirst et al. 1995, Slater et al. 1995, Fuentes et al. 1996, 
Mijovic et al. 1997, Slater et al. 1998). In contrast to fetal membranes, myometrial COX-2 
expression decreased (Zuo et al. 1994) or showed no change (Moore et al. 1999, Sparey et al. 1999) 
at the onset of labor as detected by in situ hybridization, reverse-transcriptase polymerase chain 
reaction (RT-PCR), or immunoblotting. However, Slater et al. (1999) found COX-2 mRNA and 
protein to increase at term in myometrium prior to the onset of labor, while COX-1 expression 
stayed constant or decreased. This would imply COX-2 plays a role during labor onset.  
 
Bacterial products can induce cytokine and PG biosynthesis. Increased expression of COX-2 is a 
consequence of the stimulatory effect of bacterial lipopolysaccharides (LPS) and proinflammatory 
cytokines. IL-1β , TNF-α, and other cytokines are elevated in fetal membranes and in the amniotic 
fluid of women with intra-amniotic infection (Romero et al. 1989), but also in spontaneous term 
labor (Romero et al. 1990). IL-1β stimulates the production of PGs in human myometrial cells 
(Pollard and Mitchell 1996, Gramatopoulos and Hillhouse1999) and induces COX-2 expression in 
an immortalized human myometrial smooth muscle cell line (Belt 1999). The effect of PGs on the 
function of myometrium is dependent in part on the diversity of PG receptors. The EP3 receptor is 
more prominently expressed in the fundal part of the primate uterus, whereas the relaxatory EP2 and 
EP4 receptors dominate in the lower part (Smith et al. 1998). As myometrial cells mainly produce 
PGI2 and PGE2, their main function in the lower part of the uterus is relaxation rather than 
contraction. Myometrial PG receptors are also dependent on gestational age, and in early pregnancy 
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the contractile EP3 and FP receptors are down-regulated (Matsumoto et al. 1997), whereas during 
labor at term, FP receptor expression increases (Brodt-Eppley and Myatt 1999).  
 
4. COX-2 AND CARCINOMAS 
4.1. Ovarian carcinoma 
4.1.1 Statistics on ovarian cancer  
Ovarian cancer is the second most common gynecological malignancy in the Western world, and it 
is the sixth most common cancer in females in Finland (Finnish Cancer Register 2001). Ovarian 
carcinoma is the most fatal malignancy among gynecological cancers and was the fifth most lethal 
cancer type after breast, lung, pancreas, and colon cancers in females in 2001. In Finland 478 new 
cases of ovarian cancer were diagnosed in 2001. Ovarian carcinomas, i.e., tumors originating from 
the surface epithelium, account for approximately 85 to 90% of all malignant ovarian tumors and 
exhibit several histological subtypes with different pathogenesis and outcome. The most common 
histological subtypes of epithelial ovarian carcinoma are serous, endometroid, and mucinous 
carcinoma, representing 40 to 50%, 15 to 20%, and 5 to 15% of all cases. Less common histological 
subtypes include clear cell (mesonephroid), and undifferentiated carcinoma, malignant mixed 
epithelial tumor, and transitional cell carcinoma (malignant Brenner tumor) (Heinz et al. 2001).  
 
Table 2. Mean annual numbers, incidence, deaths, and mortality from gynecological cancers in 
2001 and predicted number of cases for 2004 in Finland (Finnish Cancer Register 2001). 
 
                                                              
                      
          
 
4.1.2 Origin of ovarian cancer  
The Mϋllerian duct system forms the fallopian tubes, the uterus, and the upper part of the vagina, 
and this celomic epithelium differentiates into the mesothelial lining of the ovarian surface and the 
epithelial lining of the fallopian tubes, endometrium, and endocervix. The ovary itself is thought to 
Primary site No. of cases 
2001 
Incidence per  
100,000 
Deaths 
 in 2001 
Mortality 
per 100 000  
Predicted 
for 2004 
Corpus uteri                    633 12.7 168 2.6 750 
Ovary   478 10.2 262 4.7 471 
Cervix uteri                     160 3.8 61 1.2 142 
Vagina, vulva, tuba 115 2.0 56 0.7  
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be of mesonephroid origin, but during adult life its surface mesothelium frequently undergoes 
Mϋllerian metaplasia. Serous ovarian carcinomas are therefore morphologically similar to epithelial 
tumors arising in the fallopian tube, the mucinous arising in the endocervix, and the endometroid in 
the endometrium (Salazar et al. 1995).  
 
According to the currently favored theory, ovarian carcinomas arise from the ovarian surface 
epithelium, usually in the context of invaginations that create intraovarian cysts (Scully 1995, Aoki 
et al. 2000, Okamura and Katabuchi 2001). The etiology and early events in the progression of 
these carcinomas are not well understood compared to other human malignancies. This is due to 
lack of access to preneoplastic tissues because of the difficulty in diagnosing ovarian carcinoma at 
an early stage (Scully 1995). However, Salazar et al. (1996) have observed numerous atypical 
features in ovaries removed prophylactically from cancer-prone women when compared with those 
at no known increased risk for disease. These features included surface epithelial 
pseudostratification, surface papillomatosis, epithelial inclusion cysts with epithelial hyperplasia, 
stromal or hilar hyperplasia, and increased follicular activity, all of which are rarely seen in normal 
ovaries. Multiparity, lactation, tubal ligation, hysterectomy, and use of oral contraceptives are 
associated with decreased risk for ovarian cancer (Whittemore et al. 1992, Hankinson et al. 1993). 
Risk factors have been reported to differ between histological subtypes; the protective effects of 
parity and of oral contraceptives appear not to involve mucinous carcinoma (Kvale et al. 1988, 
Risch et al. 1996). An estimated 5 to 10% of ovarian carcinomas are of an inherited predisposition. 
Known cancer-predisposing syndromes linked to ovarian carcinoma include breast and ovarian 
cancer syndrome (BRCA1/BRCA2 genes) and the hereditary non-polyposis colorectal cancer 
(HNPCC) syndrome (Boyd and Rubin, 1997).  
  
4.1.3 Prognosis of ovarian cancer 
Of ovarian cancers, 70% are diagnosed with widespread intra-abdominal disease or distant 
metastases, which partially accounts for the poor prognosis. Stage according to the International 
Federation of Gynecology and Obstetrics (FIGO) staging system and grade of this disease at 
diagnosis are important determinants of prognosis. The five-year overall survival rate is 48%, 
ranging from 80 to 90% at stage I, 64 to 70% at stage II, and 29 to 59% at stage III, down to 17% at 
stage IV (Heinz et al. 2001). The different histological types of ovarian carcinoma show different 
clinical behavior and prognosis. The overall prognosis for mucinous ovarian carcinoma is relatively 
good (68%) due to late dissemination of the tumor cells, but the outcome in primarily advanced 
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disease is particularly poor due to resistance to the chemotherapeutic agents commonly used 
(Omura et al. 1991, Makar et al. 1995, Heinz et al. 2001). The 5-year overall survival rate for 
serous and endometroid carcinomas is 40% and 60% (Heinz et al. 2001). Serous ovarian tumors are 
more often malignant and bilateral than are mucinous tumors.  In addition to stage and grade, other 
prognostic factors of ovarian carcinoma are residual tumor size, age, and performance status, but 
not primary tumor size (Friedlander 1998).  
 
Stage and grade of ovarian carcinoma are the main determinants in decisions about treatment 
methods. Radical surgery or at least maximal debulking is the cornerstone of effective treatment of 
ovarian cancer. It is essential for accurate staging, histological classification, and grading, and it is a 
good basis for selection of adjuvant chemotherapy. Carboplatin-paclitaxel chemotherapy has been 
the first-line chemotherapy in Finland for ovarian carcinomas of stage Ib and advanced stages since 
1996. Based on the previous reports, adjuvant chemotherapy may improve overall survival and 
recurrence-free survival also in patients with early stage ovarian carcinomas.  
 
4.1.4 Prognostic markers in ovarian cancer  
Cytogenetic analyses have revealed abnormal karyotypes in approximately 50 to 90% of ovarian 
carcinomas. Cytogenetic abnormalities and their complexity are correlated with grade of ovarian 
carcinoma. Cytogenetic alterations exist most often in ovarian carcinomas of the serous type 
(Pejovic et al. 1992, Taetle et al. 1999). Aberration of the tumor-suppressor gene p53 are the most 
frequent molecular alteration detected in ovarian carcinoma (Marks et al. 1991, Klemi et al. 1995), 
and it has been predicted to confer poor prognosis (Hartmann et al. 1994, Klemi et al. 1995, Reles 
2001), whereas other studies have found no correlation between p53 status and survival (Marks et 
al. 1991, Fallows et al. 2001). Normal surface epithelium of ovaries and normal serous epithelium 
of the fallopian tube express only weak immunopositivity for the tumor suppressor gene p53, but 
this expression is either lost or enhanced in 59% of serous ovarian carcinomas (Lassus et al. 2003). 
Lassus et al. (2003) observed that prognosis of the ovarian carcinoma patients was reduced in p53-
negative or -high groups when compared to the p53-low group. Aberrant p53 expression was 
associated with poor response to therapy, high risk of recurrence, and poor overall survival also in 
well-differentiated, early-stage serous ovarian carcinomas. Thus, these two altered patterns of p53 
expression (negative or high) most likely represent loss of p53 tumor suppressor gene function, 
negative expression reflecting either loss or inactivation of the gene, and high expression represents 
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a mutation of the gene that led to stabilization of the nonfunctional p53 protein. Alterations in p53 
have been as usual in familial ovarian carcinomas as in sporadic carcinomas (Auranen et al. 1997).  
 
The distal half of chromosome 18q is among the genomic regions most frequently lost in serous 
ovarian carcinoma (Arnold et al. 1996, Tapper et al. 1998, Lassus et al. 2001). Expression of the 
tumor suppressor gene SMAD4, located at 18q21, is usually present in the normal surface 
epithelium of the ovary, but is absent or weak in 28% of serous ovarian carcinomas (Lassus et al. 
2001). In addition to inactivation of tumor suppressor genes, activation or overexpression of several 
proto-oncogenes has been detected in ovarian cancer. For example, amplification of the proto-
oncogene Her-2/neu (also known as ErbB2) occurs in approximately 30% of sporadic ovarian 
carcinomas (Hellström et al. 2001) and in nearly 70% of familial ovarian carcinomas (Auranen et 
al. 1997). The Her-2 gene encodes for a 185-kDa cell surface glycoprotein which has tyrosine 
kinase activity and belongs to the epidermal growth factor receptor family. In breast cancer, Her-2 
amplification is associated with aggressive behavior of the tumor, and with poor outcome (Ross and 
Fletcher 1999). The human anti-Her-2 monoclonal antibody (mAb) trastuzumab (Herceptin) has 
been used successfully in metastatic breast cancer with Her-2/neu amplification to gain longer 
survival for these patients (Cobleigh et al. 1999, Slamon et al. 2001). The prognostic role of Her-
2/neu in ovarian carcinoma remains controversial. In several studies, Her-2/neu overexpression or 
amplification or both have been associated with poor clinical outcome (Slamon et al. 1989, 
Berchuck et al. 1990, Meden et al. 1994, Fajac et al. 1995, Lassus et al. 2004), whereas others have 
shown no effect (Singleton et al. 1994, Skirnisdottir et al. 2001) or even an increased effect on 
survival (Haldane et al. 1990). In clinical samples, Her-2/neu overexpression can be determined by 
immunohistochemistry, but detection of the gene copy number by fluorescence in situ hybridization 
(FISH) is necessary to confirm Her-2/neu amplification (Press et al. 2002). An alternative method, 
the chromogenic in situ hybridization (CISH), using conventional bright-field microscopy, has been 
developed for detection of the amplified Her-2/neu gene (Tanner et al. 2000). Lassus et al. (2003) 
found that Her-2/neu amplification identified by CISH in serous ovarian cancer was associated with 
poor survival.  
 
4.2. COX-2 in ovarian carcinoma 
By immunohistochemistry COX-2 expression is low or undetectable in normal ovarian surface 
epithelium (Denkert et al. 2002, Landen et al. 2003, Shigemasa et al. 2003, Li et al. 2004). The 
expression of COX-2 is increased when benign ovarian tumors (COX-2 positivity 0-64%) 
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(Matsumoto et al. 2001b, Klimp et al. 2001, Denkert et al. 2002) and tumors with low malignant 
potential (COX-2 positivity 37-67%) (Matsumoto et al. 2001b, Klimp et al. 2001, Denkert et al. 
2002) are compared with invasive carcinomas (COX-2 positivity 31-83%, Table 3) (Matsumoto et 
al. 2001b, Klimp et al. 2001, Denkert et al. 2002, Ferrandina et al. 2002a and b, Shigemasa et al. 
2003, Ali-Fehmi et al. 2003, Li et al. 2004, Raspollini et al. 2004, Seo et al. 2004). This relatively 
high variation in COX-2 positivity may depend on the use of different antibodies, scoring criteria, 
and selection of patients. Only Shigemasa et al. (2003) and Seo et al. (2004) examined COX-2 
expression in different histological subgroups, whereas other researchers considered all ovarian 
cancer histologies as a single entity. Shigemasa et al. (2003) found a significant difference in 
frequency of COX-2 expression between endometrioid (56% of 16) versus mucinous (17% of 18), 
and endometrioid versus clear cell (14% of 14) carcinomas, but not between serous (34% of 38) 
ovarian carcinomas versus other histological subtypes. According to the Seo et al. study (2004), the 
COX-2 expressing tumors were more common among nonmucinous (65% of 46) than mucinous 
(6% of 18) ovarian carcinoma histologies. Methods other than immunohistochemistry have also 
been used to observe the expression of COX-2. Denkert et al. (2002) and Shigemasa et al. (2003) 
used the reverse transcriptase polymerase chain reaction (RT-PCR), and Ferrandina et al.  (2002a) 
and Li et al.  (2004) used Western blotting to investigate COX-2 expression. Expression of COX-2 
appeared in 42 to 100% of ovarian tumors by immunoblotting and in 72 to 88% by RT-PCR. 
According to most studies COX-2 expression occurs in epithelial carcinoma cells of ovarian tumors, 
but only a few studies have shown stromal COX-2 expression in macrophages (Klimp et al. 2001) 
or in lymphoid cells (Ferrandina et al. 2002 a and b).  
 
Elevated expression of COX-2 in epithelial cancer cells is associated with reduced survival 
(Ferrandina et al. 2002a and b, Sigemasa et al. 2003, Ali-Fehmi et al. 2003, Seo et al. 2004, 
Raspollini et al. 2004), especially in patients over 60 years old (Denkert et al. 2002). COX-2 
expression is an independent prognostic factor for poor survival (Denkert et al. 2002) and reduced 
likelihood of response to chemotherapy in multivariate analysis (Ferrandina et al. 2002a and b, 
Raspollini et al. 2004). Seo et al. (2004) observed the high COX-2 expression to associate with 
clinical factors such as histological type, stage, grade, presence of ascites, and residual tumor size. 
However, many studies show no correlation between COX-2 expression and clinical factors 
(Matsumoto et al. 2001, Denkert et al. 2002, Ferrandina et al. 2002a, Shigemasa et al. 2003, Li et 
al. 2004). 
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Table 3. Expression of COX-2 in benign, low malignant potential (LMP) and malignant ovarian 
tumors. 
 
Method                COX-2 positive tumors % (n1)  
 Benign LMP2 Malignant Reference 
Immunohistochemistry 0% (3) 0% (3) 0% (13) Dore et al. 1998  
 50% (8) 67% (21) 79% (28) Matsumoto et al. 2001b 
 64% (14) 67% (15) 83% (18) Klimp et al. 2001 
 0% (14) 37% (19) 42% (86) Denkert et al. 2002 
 ND3 ND 47% (76) Ferrandina et al. 2002a 
 ND ND 45% (87) Ferrandina et al. 2002b 
 0% (6) ND 14-56%4 (86) Shigemasa et al. 2003 
 ND ND 68% (125) Ali-Fehmi et al. 2003 
 0% (9) ND 71% (137) Li et al. 2004 
 ND ND 69% (78) Raspollini et al. 2004 
 ND ND 6-65%5 (64) Seo et al. 2004 
Western blotting ND ND 100% (2) Ferrandina et al. 2002a 
RT-PCR6 ND 100% (1) 88% (8) Denkert et al. 2002 
 ND ND 72% (36) Shigemasa et al. 2003 
Immunofluorecence 0% (13) ND 89% (9) Landen et al. 2003 
 
1 Total number of tumors investigated 
2 Low malignant potential 
3 Not determined 
4 Percentage of COX-2-positive tumors (%) in different ovarian carcinoma histologies; clear cell carcinoma   14% 
(n=14), mucinous carcinoma17% (n=18), serous carcinoma 34% (n=38), and endometrioid carcinoma 56% (n=16). 
5 Percentage of COX-2-positive tumors (%) in mucinous 6% (n=18) and in nonmucinous 65% (n=46) ovarian 
carcinomas.   
6 Reverse transcriptase polymerase chain reaction 
 
 
4.3 COX-2 in other gynecological malignancies 
4.3.1 Cervical cancer      
COX-2 protein expression appeared in 25 to 100% of invasive cervical carcinomas as detected by 
immunohistochemistry (Table 4) (Ruy et al. 2000, Kulkarni et al. 2001, Gaffney et al.. 2001, Sales 
et al. 2001, Ferrandina et al. 2002c, Kim et al. 2002, Landen et al. 2003). COX-2 expression is 
especially high in the invasive edge of the tumor (Ruy et al. 2000). In severe cervical intraepithelial 
dysplasia (carcinoma in situ) (Kulkarni et al. 2001) and in cervical carcinoma, COX-2 expression is 
localized in the transformed epithelial cells (Ruy et al. 2000, Sales et al. 2001, Kulkarni et al. 2001, 
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Gaffney et al. 2001, Ferrandina et al. 2002c, Kim et al. 2002, Landen et al. 2003) and also in 
stromal cells (Kim et al. 2002, Ferrandina et al. 2002c) and in vascular endothelial cells (Sales et al. 
2001). Elevated COX-2 expression is associated with high age (Ferrandina et al. 2002c), large 
tumor size (Gaffney et al. 2001, Ferrandina et al. 2002c), adenocarcinoma-like histology 
(Ferrandina et al. 2002c), and parametrial invasion (Ruy et al. 2000, Ferrandina et al. 2002c), but 
not with stage or grade (Ferrandina et al. 2002c, Kim et al. 2002). Patients with COX-2-positive 
cervical cancer show significantly shorter overall survival than do patients with the COX-2-negative 
carcinoma (Gaffney et al. 2001, Ferrandina et al. 2002c, Kim et al. 2002). The percentage of COX-
2-positive tumors is higher among patients not responding to treatment than among patients with 
partial or complete response (Ferrandina et al. 2002c, Kim et al. 2002). 
 
 
Table 4. Expression of COX-2 in normal uterine cervix, carcinoma in situ of the uterine cervix, and 
cervical carcinoma detected by immunohistochemical methods.  
  
 Elevated Cox-2%/ (n)   
Normal Carcinoma in situ Carcinoma Reference 
ND1 ND 100% (36) Ruy et al. 2000 
0% (13) 100% (1) 92% (13) Kulkarni et al. 2001 
ND ND 83% (24) Gaffney et al. 2001 
0% (5) ND 100% (10) Sales et al. 2001 
ND ND 43% (8) Ferrandina et al. 2002c 
ND ND 30% (75) Kim et al. 2002 
50% (14) ND 25%(12) Landen et al. 2003 
  
1 Not determined 
 
4.3.2 Endometrial cancer  
COX-2 is overexpressed in 39 to 92% of endometrial adenocarcinomas as detected by IHC (Table 
5) (Tong et al. 2000, Uotila et al. 2002, Cao et al. 2002, Fujiwaki et al. 2002, Ferrandina et al. 
2002d, Landen et al. 2003). In endometrial adenocarcinoma, COX-2 expression localized in 
epithelial carcinoma cells (Fujiwaki et al. 2002, Uotila et al. 2002) but not in stromal cells (Cao et 
al. 2002). COX-2 expression correlated with high grade and stage of endometrial carcinoma, but 
there was no correlation of COX-2 expression with survival of patients (Ferrandina et al. 2002d, 
Cao et al. 2002).  
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Table 5. Expression of COX-2 in normal endometrium and endometrial adenocarcinoma detected 
by immunohistochemical methods. 
 
 
1 Not determined 
 
 
4.4 COX-2 in other malignancies 
Several different types of carcinomas express COX-2 and produce PGs. Numerous studies have 
concentrated on colorectal carcinogenesis. Elevated levels of COX-2 mRNA and protein have been 
detected in 75 to 100% of human colorectal cancers and approximately 50% of preneoplastic 
lesions (Eberhart et al. 1994, Sano et al. 1995, DuBois et al. 1998). Expression of COX-2 correlates 
with poor survival in colorectal carcinoma (Masunaga et al. 2000), in adenocarcinoma of the 
esophagus (Buskens et al. 2002), and in breast carcinoma (Ristimäki et al. 2002).  Finally, 
expression of COX-2 and its role in cancer formation may not be restricted to the carcinomas, since 
COX-2 is expressed in glioma (Deininger et al. 1999), melanoma (Denkert et al. 2001), and 
retinoblastoma (Karim et al. 2000).  
 
 Elevated COX-2 %/ (n)  
Normal Carcinoma Reference 
86% (7) 92% (12) Uotila et al. 2002 
0% (3) 73% (11) Tong et al. 2000 
ND1 39% (69) Ferrandina et al. 2002 
ND ND Cao et al. 2002 
ND ND Fujiwaki et al. 2002 
7% (15) 69%(13) Landen et al. 2003 
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AIMS OF THE STUDY 
Regulation of PG synthesis is known to play a role in many physiological processes and is involved 
in tumor formation. The purpose of this study was to investigate the expression of COX-2, an 
inducible enzyme of PG synthesis,  in gynecological organs in benign and malignant processes.  
Myometrial smooth muscle of the uterus was selected as a representative benign tissue type and 
serous and mucinous types of ovarian carcinoma as a model of the malignant process.  
 
 
 
The specific aims were: 
 To investigate the expression of COX-2 protein in myometrium of the term pregnant 
uterus in labor in comparison with the uterus not in labor and to study the regulation of COX-2 
expression in cultured human myometrial cells. (Study I) 
 
 To observe  the significance of COX-2 protein expression in ovarian carcinoma and 
study correlations of expression of COX-2 with clinically meaningful parameters and patient 
survival in serous and in mucinous ovarian carcinoma. (Studies II and IV) 
 
 To study whether mRNA-stabilizing HuR protein is connected with COX-2 
expression in serous and mucinous ovarian carcinoma. Finally, to investigate whether expression of 
HuR itself correlates with clinically meaningful parameters including patient survival (Studies III 
and IV). 
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MATERIALS AND METHODS 
1. HUMAN TISSUE SPECIMENS (I-IV) 
 
All myometrial tissues and neoplastic and nonneoplastic ovarial tissues were obtained from the 
Department of Obstetrics and Gynecology of Helsinki University Central Hospital, Finland. The 
study was approved by the local Ethics Committee. Myometrial tissues were collected in gestation 
weeks 37 to 42 from 25 healthy women, of which 10 were in labor and 15 not in labor at the time of 
cesarean section. The cesarean section was done because of disproportion or breech presentation. 
Ten women in labor had been in labor for 6 to 22 h, and the time elapsed from the rupture of fetal 
membranes was 4 to 24 h, after which mostly all had their cervix opened. Fifteen women not in 
labor had no contractions, and their fetal membranes were intact. Preterm cesarean sections were 
excluded because of the possibility of subclinical infections or maternal health problems, which 
may cause induction of PG synthesis. All myometrial samples from pregnant women were collected 
from the upper edge of the uterine incision during lower-segment cesarean section. Myometrial 
control sample came from fertile woman during hysterectomy for myomatous uterus.  
 
All serous ovarian cancer specimens were collected between the years 1964 and 2000 and mucinous 
specimens between the years 1989 and 2000 in primary operations before patients had received any 
chemotherapy (Table 6 and 7). The histology was determined by a gynecological pathologist and 
was verified by another pathologist (R.B.). The clinical information of the patients was extracted 
from the patient records and survival information from the Population Register Center. The median 
age of serous ovarian carcinoma patients was 57 years (range, 15-88 years) and of mucinous 
carcinoma patients 54 years (range, 24-84 years) at the time of diagnosis. The median follow-up 
time of patients alive at the end of study period was 5.2 years (range, 0.4-36.1 years) in serous and 
4.4 years (range, 0.06 -10.28 years) in mucinous ovarian carcinoma patients. The clinical staging 
and grading were performed according to the FIGO. New treatment regimens were adopted as 
follows: platinum-based chemotherapy at the beginning of the 1980s; radical surgery at the end of 
the 1980s; and paclitaxel/platinum chemotherapy after 1996.  
 
Tissue microarrays were constructed by selecting a representative tumor area from hematoxylin-
eosin-stained sections of each tumor by our pathologist (R. B.). Four tissue cores (diameter 0.8 mm) 
were obtained from each tumor block, and replaced into a recipient paraffin block with a custom-
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built precision instrument (Beecher Instruments, Silver Spring, MD). These samples were cut with a 
microtome into 5 µm-sections, and the presence of cancer cells was verified on hematoxylin-eosin-
stained sections. 
  
 
Table 6. Summary of human tissue samples and methods used in studies 
 
Tissue Methods used (number of samples analyzed) Study 
Myometrium   
In labor Northern blot (10) Immunohistochemistry (2) I 
   
Not in labor Northern blot (15) I 
   
Not pregnant Northern blot (1) I 
Ovary   
Normal Immunohistochemistry (6) II, IV 
   
Serous carcinoma 
Immunohistochemistry (474 array, 12 histological)  
Western blot (12) RT-PCR1 (12) II, III 
   
Mucinous carcinoma 
Immunohistochemistry (64 array, 12 histological) 
Western blot (3) RT-PCR (3) 
IV 
NP2 
 
1 Reverse transcriptase polymerase chain reaction 
2 Not published 
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Table 7. Clinical features of 474 serous and 64 mucinous ovarian carcinoma patients. 
  
 Serous ovarian carcinoma Mucinous ovarian carcinoma 
Clinical feature n / total (%) n / total (%) 
Age   
≤ 57 (serous)/ ≤ 54 (mucinous)1 238/474 (50%) 33/64 (52%) 
> 57(serous)/ > 54 (mucinous) 236/474 (50%) 31/64 (48%) 
Grade   
1 181/466 (39%) 50/64 (78%) 
2 121/466 (26%) 13/64 (20%) 
3 164/466 (35%) 1/64 (2%) 
Stage   
I 101/471(21%) 50/64 (78%) 
II 64/471 (14%) 3/64 (5%) 
III 251/471 (53%) 10/64 (16%) 
IV 55/471 (12%) 1/64 (2%) 
Status after follow-up2   
deceased 262/474 (55%) 9/64 (14%) 
living 212/474 (45%) 55/64 (86%) 
Tumor size   
≤ 10 cm 152/467 (33%) ND3 
> 10 cm 315/467 (67%) ND  
Residual tumor size   
≤ 1cm 216/423 (51%) ND 
> 1 cm 207/423 (49%) ND  
p53   
negative 69/460 (15%) 0/50 (0%) 
normal 193/460 (42%) 40/50 (80%) 
overexpression 198/460 (43%) 10/50 (20%)  
SMAD4   
negative 33/457 (7%) ND 
low 117/457 (26%) ND  
moderate 255/457 (56%) ND 
high 52/457 (11%) ND  
HER-2/neu   
normal 300/381 (79%) 35/39 (90%) 
amplified 81/381 (21%) 4/39 (10%)  
Inhibin-α   
negative ND 7/58 (12%) 
positive ND  51/58 (88%) 
 
1 Mean age at diagnosis in serous carcinoma was 57 years and 54 years in mucinous carcinoma. 
2 Mean follow-up time for serous carcinomas 5.2 years (range, 0.4-36.1 years) and for mucinous carcinomas 4.4 years 
(range, 0.06-10.28 years). 
3 Not determined 
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2. CELL CULTURE EXPERIMENTS (I-IV) 
Myometrial cells were isolated from tissues obtained from either lower-segment elective cesarean 
sections at term (three separate cell lines) and a control cell line from the uterus of a nonpregnant 
patient who underwent hysterectomy for myomatous uterus. The specimens were digested with 
collagenase (0.2%, type IV, Sigma, St. Louis, MO, USA) and trypsin (0.05%, Life Technologies, 
Inc., Paisley, Scotland) in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 20 
mmol/L N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES, Life Technologies, Inc.), 2 
mmol/L L-glutamine, and antibiotics for 2h in 37˚C at 5% CO2 in air. Primary cultures were grown 
in DMEM supplemented with 10% fetal calf serum (FCS, Hyclone Laboratories, Inc.), L-glutamine, 
and antibiotics in 75 cm2 tissue culture flasks (Nunc, Roskilde, Denmark). The cells were used at 
passages 2 to 7, and exhibited positive staining for monoclonal antihuman α-smooth muscle actin 
antibody (α-SMA, 1:1000, DAKO Corp., Klostrup, Denmark), which stains smooth muscle cells, 
but not fibroblasts. These cells grew in a “hill and valley” pattern, and their proliferation rate was 
quite low, which differs from that of fibroblasts. Cultured smooth muscle cells have been described 
to retain their morphological and biochemical properties through 16 passages and for at least one 
year (Casey et al. 1984). All this indicates that the cells used in our experiments represented 
myometrial smooth muscle cells. Before the experiments the cells were starved for 48 h in 0.5% 
FCS in DMEM, and all incubations were carried out in 0.5% FCS without (control) or with IL-1β, 
PMA, oxytocin, TNF-α, dexamethasone, and COX-2 selective inhibitor NS-398 (Table 8). 
 
We had three human serous ovarian carcinoma cell lines: OVCAR-3, CaOV-3, and ES-2 (ATCC, 
Rockville, MD, USA), and EFO-27 that originated from a mucinous ovarian carcinoma (DSMZ, 
Frankfurt, Germany). OVCAR-3 cells were cultured in DMEM and CaOV-3, ES-2, and EFO-27 in 
RPMI cell culture medium supplemented with 10% FCS, L-glutamine, and antibiotics. The 
expression of COX-2 in OVCAR-3 (Table 8), CaOv-3, ES-2, and EFO-27 was studied by 
stimulating these cell lines with IL-1β or PMA.  
 
The small interfering (si)RNA duplexes against HuR and β-actin were synthesized by Dharmacon 
Inc. (Lafayette, CO, USA), and the sequences were: HuR Sense 5’-AAC AUG ACC CAG GAU 
GAG UUA dTdT-3’ and HuR Antisense 5’-UAA CUC AUC CUG GGU CAU GUU dTdT-3’. The 
β-actin siRNA sequence were: β-actin Sense 5’-AAU GAA GAU CAA GAU CAC UGC dTdT-3’ 
and β-actin Antisense 5’-GCA AUG AUC UUG AUC UUC AUU dTdT-3’. The day before 
transfection, OVCAR-3 cells were trypsinized and diluted 1:20 with optiMEM 1-medium (Life 
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Technologies, Inc. Invitrogen) supplemented with 10% FCS without antibiotics and transferred to 
12-well plates, 1 ml per well (final split ratio 1:2). Transient transfection of siRNAs was carried out 
using Oligofectamine Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to 
manufacturer's instructions. First, 8 µl OptiMEM medium and 2 µl Oligofectamine were mixed, and 
at the same time 85 µl OptiMEM was mixed with 5 µl of HuR or β-actin siRNA (20 µM) duplexes. 
These two reactions were incubated separately for 10 min at room temperature, after which they 
were combined and incubated for 20 min at room temperature for complex formation. The cells 
were washed once with serum- and antibiotic-free OptiMEM, and 400 µl of OptiMEM and 100 µl 
of the transfection mixture was added to the cells. The cells were incubated for 4 hours at 37°C at 
5% CO2 in a cell incubator after which 250 µl of 3x serum medium (30% FCS in OptiMEM with 
penicillin and streptomycin) was added. The final siRNA concentration in 500 µl was 200 nM. The 
cells were incubated with the siRNA molecules for 72h, and IL-1β (10 ng/ml) was added for the last 
24 h of the incubation period. In the LMB (Sigma) experiment, the cells were incubated with LMB 
(5-10 ng/ml) in combination with IL-1β for 24 h.  
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Table 8. Agents and concentrations in cell culture experiments. 
 
 
3. ENZYME-LINKED IMMUNOASSAY (EIA) AND RADIOIMMUNOASSAY (RIA) 
(I) 
Myometrial cells were incubated after 48 h starvation in 10-cm2 tissue culture dishes (Nunc, 
Roskilde, Denmark) with test agents for 6 hours, after which the cells were washed and incubated 
with AA (10 µM, Sigma) for 10 min. PGE2 and PGF2α were analyzed by EIA according to the 
manufacturer’s protocol (Cayman Chemical Co., Ann Arbor, MI, USA) and 6-keto PGF1α, a stable 
hydrolysis product of PGI2 by RIA (Amershamn Pharmacia Biotech, Uppsala, Sweden) employing 
specific antibodies and a tritiated 6-keto-PGF1α. 
 
Cell line Agents Substance concentration Parameter analyzed  Study 
Myometrial IL-1β 0.01-10 ng/ml  COX-2 protein I 
 
IL-1β 
 
 
10 ng/ml 
 
 
COX-2 protein, 
6-ketoPGF1α, PGE2, PGF2α,  
and mRNAs for EP2 and EP4 I 
 
PMA 
 
10 ng/ml  
 
COX-2 protein, 6-ketoPGF1α, and 
mRNAs for EP2 and EP4 I 
 Oxytocin 0.4 nM COX-2 protein I 
 TNF-α 100 ng/ml COX-2 protein I 
 Dexamethasone 1 µM COX-2 protein I 
 NS-398 15 µM COX-2 protein , 6-keto PGF1α I 
 Indomethacin 10 µM 6-keto PGF1α I 
OVCAR-3 IL-1β 10 ng/ml Proteins for COX-2, HuR, β-actin III 
 HuR siRNA 200 nM Proteins for COX-2, HuR, β-actin III 
 LMB 5 and 10 ng/ml Proteins for COX-2, HuR, β-actin III 
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4. IMMUNOHISTOCHEMISTRY (I-IV) 
Formalin-fixed, paraffin-embedded specimens were deparaffinized and antigen retrieved with 
microwave oven (4x5 min in 700 W in 0.01 M Na-citrate buffer, pH=6). The slides were then 
immersed in 0.6% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase 
activity. After that the slides were immersed in blocking solution (1.5:100 normal horse serum in 
PBS) for 15 min to block unspecific binding sites. Immunostaining was performed with a COX-2-
specific antihuman monoclonal antibody (160112; Cayman) at a dilution of 1:200 (2.5 µg/ml) or 
with a HuR monoclonal antibody 19F12 (Wang et al. 2000, Clonegene LCC, Hartford, CT, USA) at 
a dilution of 1:10 000 (1.0 µg/ml) in PBS containing 0.1% sodium azide and 0.5% bovine serum 
albumin (Table 9). HuR antibody which was raised against a unique peptide from the NH2-terminus 
of HuR. The specimens were incubated with the antibody at room temperature overnight. The 
sections were then treated with biotinylated horse anti-mouse immunoglobulin (1:200; Vector 
Laboratories Inc., Burlingame, CA, USA) and avidin-biotin peroxidase complex (Vectastain 
ABComplex, Vector). The peroxidase staining was visualized with 3-amino-9-ethylcarbazole 
(Sigma), and the sections were counterstained with Mayer's hematoxylin. To confirm the specificity 
of the COX-2 staining, twelve sections with serous and mucinous ovarian cancer and six 
nonneoplastic ovarian samples were stained with and without human COX-2 control peptide (20 
µg/ml, Cayman) for one hour at room temperature prior to the staining procedure. To confirm the 
specificity of the HuR staining, nine histological sections with serous and four sections with 
mucinous ovarian carcinomas were stained with and without the antigenic peptide for 19F12 (10 
µg/ml) for one hour at room temperature prior to the staining procedure.  
 
Table 9. Antibodies used in immunohistochemistry (IHC). 
 
Primary Antibody  
Dilution used in 
IHC1 
Dilution used in 
WB2 Source Study 
Rabbit anti-mouse Cox-2 affinity-purified 1:250 1:1000 Cayman I 
polyclonal IgG (160126)     
Mouse anti-human COX-2 monoclonal 1:200 (2.5µg/ml) 1:1000 Cayman II-IV 
antibody (160112)     
Mouse HuR monoclonal 1:10 000 (1.0µg/ml) 1:100 000 Clonegene III, IV 
antibody (19F12)     
 
1 Immunohistochemistry 
2 Western blot 
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5. SCORING OF IMMUNOHISTOCHEMISTRY (II-IV) 
The intensity of COX-2 staining in both epithelial and stromal cells was scored independently and 
in a blinded manner by three investigators (T-L. E., B. v R., and A. R.) from 474 serous and by two 
investigators (T-L. E., A. S.) from 64 mucinous ovarian carcinoma tissue cores on the scale 
presented in Table 10. Only those tumors that exhibited at least three tissue cores were included in 
analysis: serous 93% (442 of 474) and mucinous 88% (56 of 64). Since one mucinous tumor 
contained no stroma, the final scores for mucinous stromal COX-2 expression were obtained from 
55 tumors. All specimens with discordant scores were re-evaluated with a multiheaded microscope, 
and the consensus score was used for further analyses.  
 
The intensity of staining of HuR protein was scored in cancer cells and in non-neoplastic stromal 
cells by two independent and blinded investigators (T-L. E. and A. S.) in the serous and mucinous 
ovarian specimens. Only those tumors from which at least three cores remained analyzable after the 
immunostaining procedure were scored (serous 96%, 445 of 474 and mucinous 89%, 57 of 64). 
Since one mucinous tumor contained no stroma, the final scores for mucinous stromal HuR 
expression were obtained from 56 tumors. The localization and intensity of immunoreactivity in 
nucleus and cytoplasm were scored separately on the scale presented in the Table 10. In HuR 
immunohistochemical analysis, the independent investigators scored every immunopositive region, 
and the score of the tumor was the most common score found. The percentage-agreement between 
the two independent and blinded investigators in allocation of the tumors into cytoplasm-negative 
and cytoplasm-positive categories was 96% (serous) and 89% (mucinous). 
 
When immunoreactivity of inhibin-α was under 10% of all stromal cells, the inhibin-α score was 1. 
When immunoreactivity was over 10%, but under 50% of all stromal cells, the score was 2, and 
otherwise 3. Only those tumors that exhibited at least three cores were included to the analysis 
(55/64, 86%). The scoring of immunoreactivity for p53 (Lassus et al. 2003), SMAD4 (Lassus et al. 
2001), and HER-2/neu (Lassus et al. 2004) has been described in previous studies.  
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Table 10. Scoring criteria for COX-2, HuR, and inhibin-α immunoreactivity. 
Protein Score Protein expression Used in  
COX-2 0 no staining II, III, IV 
 1 weak diffuse, moderate to strong <10%  
 2 moderate, strong granular 10-50%  
 3 strong granular > 50%  
 Low scores 0-1  
 High  scores 2-3  
HuR 0 negative III, IV 
 1 only nuclear  
 2 only cytoplasmic  
 3 nuclear > cytoplasmic  
 4 cytoplasmic > nuclear  
 Nuclear score 1  
 Cytoplasmic scores 2-4  
Inhibin-α (stromal) 0 negative IV 
 1 < 10%  
 2 10-50%  
 3 > 50%  
 
 
 
6. RNA ISOLATION AND NORTHERN BLOT (I) 
Total RNA was extracted by the guanidine isothiocyanate-cesium chloride method from myometrial 
tissues (Chirgwin et al. 1979) and from cultured myometrial cells with TRIzol reagent (Life 
Technologies, Inc.). Tumor samples (100 mg) of 12 serous and 3 mucinous ovarian carcinoma 
specimens were crushed in 1 ml of TriZol by the Fast Prep instrument, after which RNA was 
purified by isopropanol precipitation following the phenol/chloroform extraction. For Northern blot 
analysis, 20 µg of RNA was denaturated and electrophorezed through 1.2% agarose gel. The RNA 
was transferred to nylon membranes (Micron Separation, Inc., Westborough, MA, USA), and 
immobilized by heating at 80˚C for 1 h and cross-linked under UV light for 6 min (Reprostar II UV, 
Camag, Muttenz, Switzerland). Purified cDNA fragments of human COX-2 open reading frame 
(ORF) (1.8 kb), and GAPDH (0.8kb) were labeled with (α-32P) deoxy-CTP (DuPont-NEN life 
Science Products, Boston, MA, USA) and Prime-a-Gene kit (Promega Corp., Madison, WI, USA). 
cDNAs from human ORF of EP1, EP3, EP4, FP, and IP receptors were gifts from Merck Frosst 
Canada Inc, and the cDNA for human EP2 receptor ORF was a gift from Dr. John W. Regan, 
University of Arizona (Tucson, AZ, USA). Northern blots were visualized by autoradiography and 
were quantitated with NIH Image 1.57 on a Macintosh personal computer. 
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7. RT-PCR (III) 
Total RNA (1 µg) was converted to cDNA with Moloney murine leukemia virus (M-MLV) reverse 
transcriptase RNase H minus, RNasin (Promega), 2’deoxynucleoside 5’triphosphates (dNTP) 
(Pharmacia), and random primers (Invitrogen). The reverse transcriptase reaction mix of 5 µl was 
PCR amplified in a reaction mixture of 45 µl that contained 10x Dynazyme buffer, 2 units of 
Dynazyme II polymerase (Finnzymes, Espoo, Finland), and antisense and sense primers for COX-2 
(0.5 µg) enzyme or GAPDH (0.15 µg). The nucleotide sequences of the primer for COX-2: 5'-TTC 
AAA TGA GAT TGT GGG AAA AT-3' (sense) and 5'-AGA TCA TCT CTG CCT GAG TAT 
CTT-3' (antisense); and for GAPDH: 5'-CCA CCC ATG GCA AAT TCC ATG GCA-3' (sense) and 
5'- TCT AGA CGG CAG GTC AGG TCC ACC-3' (antisense) (Ristimäki et al. 1994). The PCR 
reaction mixture was heated to 94°C for 3 min followed by amplification for COX-2 by 40 and for 
GAPDH by 35 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension 
at 72°C for 1 min. After the last cycle, the reactions remained at 72°C for an additional 15 min. 
Amplified cDNAs were analyzed by 1.2% agarose gel electrophoresis and ethidium bromide 
staining. The amplified products were visualized under UV transillumination in MultiImageTM FC 
Light Cabinet by use of digital imaging FluorChemTM 8800 software (Alpha Innotech Corporation, 
San Leandro, CA, USA). 
 
8. WESTERN BLOT (I-IV) 
Tumor samples (50 mg) of 12 serous (Study II) and 3 mucinous (not published) ovarian carcinoma 
specimens were crushed in 1 ml of radioimmunopresipitation assay buffer (150 mM NaCl, 1% NP-
40, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, and 50 mM Tris pH 8.0) supplemented 
with a Complete mini protease inhibitor mixture tablet (Boehringer Mannheim, Germany) by the 
Fast Prep homogenization instrument (Qbiogene Inc., Carlsbad, CA, USA). The OVCAR-3 cells 
from the HuR siRNA experiment (Study III) were lysed in 400 µl (95°C) lysis buffer (60 mM Tris-
HCl pH 6.8), 2% SDS, 10% glycerol, 1% 2-mercaptoethanol, 0.002% bromophenol blue). 
Alternatively, the myometrial cells (Study I) and OVCAR-3 cells from the LMB experiments 
(Study III) were lysed in 1 ml of radioimmunopresipitation assay buffer. The amount of proteins 
was determined by BSA protein assay (Pierce, Rockford, IL, USA). From tumor samples, 100 µg of 
protein and 75 µg of protein from cell culture experiments were separated by SDS-PAGE (12%), 
and transferred electrophoretically to Hybond-C extra nitrocellulose membranes (Amersham, 
Buckinghamshire, UK). Nonspecific binding was blocked by Tris-buffered saline nonidet P40 
(TBS-NP40) and 5% low-fat dry milk solution overnight at 4˚C . For immunodetection, the 
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membrane was incubated with anti-mouse COX-2 polyclonal immunoglobulin (1:1000, Cayman, 
Study I), the monoclonal COX-2 antibody (1:1000 dilution) with or without the COX-2 blocking 
peptide (20 µg/ml, 360 107, Cayman Chemical Co., Studies III, IV), with 19F12 monoclonal HuR 
antibody (1:100 000, Study III), or with β-actin antibody (1:500 dilution, Santa Cruz 
Biotechnology, Santa Cruz, CA; Studies II- IV). The blocking procedure abolished the signal for 
COX-2 protein, thus confirming the specificity of the COX-2 antibody.  
 
The secondary antibodies for polyclonal COX-2 were goat anti-rabbit antibodies (1:2000), for 
monoclonal COX-2 and HuR, sheep antimouse antibodies (1:2000 dilution), and for β-actin, 
donkey antigoat antibodies conjugated to horseradish peroxidase (1:2000 dilution, Santa Cruz 
Biotechnology). COX-2 protein was visualized by enhanced chemiluminescence (ECL) with the 
Super Signal West Femto Maximum Sensitivity Substrate (Pierce) according to the manufacturer’s 
protocol by MultiImageTM FC Light Cabinet (Promega) and the digital imaging FluorChemTM 8800 
software (Alpha Innotech Co., San Leandro, CA, USA).  
 
9. STATISTICAL ANALYSIS 
For statistical analysis, COX-2 scores 0 and 1 were combined as low COX-2 expression, and scores 
2 and 3 represented high COX-2 expression. The correlation between COX-2 and HuR staining 
intensity and clinically relevant and prognostic variables were assessed by Chi-square test or by 
Fisher’s exact test. Probability of survival was estimated by the Kaplan-Meier method. Survival 
probabilities were compared between groups by using the log-rank test or log-rank test for trend. 
Disease-specific survival time was defined as the time from primary surgery to death of the patient 
from ovarian cancer or to the end of follow-up. Deaths due to causes other than ovarian cancer were 
treated as censored cases, as were those patients alive at the end of follow-up. Multivariate survival 
analysis was performed by the COX proportional hazards model, entering the variables significant 
for survival of patients in univariate analysis. 
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Table 11. Statistical analyses. 
Analysis Used for Study 
Student's t-test Correlation between variables I 
Mann-Whitney U-test Correlation between variables I 
Spearman correlation Correlation between variables I 
Descriptive statistics Frequency of phenomenon II, III, IV 
Chi-square test Correlation between variables II, III, IV 
Fisher's exact test Correlation between variables II, III, IV 
Kaplan-Meier test Survival analysis II, III, IV 
Log-rank test or log-rank test for trend Correlation between variables II, III, IV 
COX proportional hazard Multivariate analysis II, III 
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RESULTS 
1. COX-2 EXPRESSION IN MYOMETRIUM (I) 
1.1. COX-2 expression in pregnant myometrium in vivo 
Myometrial tissues were collected at cesarean section from 25 healthy pregnant women at gestation 
weeks 37 to 42. Of these women, 10 were in labor, they had had regular contractions for 6 to 22 h 
(mean 14.3±1.9 h), the cervix of each was open (6.6±0.9cm) except for one patient with a closed 
cervix, and 4 to 24 h (12.9±2.1 h) had elapsed following rupture of the membranes. All these 
patients received oxytocin treatment to increase contractile activity. Of these 25 women, 15 
underwent elective cesarean section, and these did not have regular contractions, their fetal 
membranes were intact, and they had no infection.  
 
Myometrial samples collected from women in labor expressed elevated levels of COX-2 mRNA 
(15.2±3.5 -fold, p<0.0001) compared to myometrial specimens collected from women not in labor 
as detected by Northern blot analysis. All non-labor specimens contained either low or undetectable 
levels of the transcript. Expression level of COX-2 mRNA was not associated with the duration of 
regular contractions, rupture of fetal membranes, or cervical situation. Immunohistochemically 
detected COX-2 protein occurred in the cytoplasm of the smooth muscle cells, and there was also 
weak COX-2 staining in the smooth muscle cells of the veins.  
 
1.2. Regulation of COX-2 expression in myometrial cells in vitro   
Myometrial cells isolated from the pregnant uterus during cesarean section and from the non-
pregnant uterus during hysterectomy were cultured for passages 2 to 7. COX-2 mRNA expression 
was low or undetectable under baseline conditions. The expression was, however, induced with IL-
1β, TNF-α, PMA, but not with oxytocin. IL-1β-induced COX-2 expression was concentration- and 
time-dependent. The peak induction was achieved by stimulation of myometrial cell lines with IL-
1β (10ng/ml) for 6 h, at which time COX-2 mRNA expression was stimulated by 17.1±1.5-fold in 
comparison with the basal expression in these cell lines (p<0.0001). An identical pattern of 
induction of COX-2 mRNA was found also in myometrial cell cultures isolated from the non-
pregnant uterus. Dexamethasone, but not the selective COX-2 inhibitor NS-398, could block the 
inductive effect of IL-1β on COX-2 mRNA expression. IL-1β and PMA also induced expression of 
COX-2 protein as detected by immunofluorescence staining and Western blot analysis. Consistent 
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with our mRNA data, IL-1β, TNF-α, and PMA but not oxytocin induced release of 6-ketoPGF1α, a 
stable hydrolysis product of PGI2. Synthesis of 6-ketoPGF1α was blocked by the selective COX-2 
inhibitor NS-398, dexamethasone, and the nonselective NSAID indomethacin. Indomethacin could 
also suppress the basal, presumably COX-1-dependent, release of 6-ketoPGF1α. Cultured 
myometrial cells expressed high levels of PGE2 receptor subtype EP2 mRNA, but only low levels of 
EP1, EP3, EP4, FP, and IP receptors.  
 
 
2. COX-2 EXPRESSION IN SEROUS AND MUCINOUS OVARIAN CARCINOMA 
(II, IV)  
2.1. COX-2 expression in serous and mucinous ovarian carcinomas in vivo and 
in vitro 
COX-2 protein expression, as detected by immunohistochemistry, localized mainly to the 
cytoplasm and to the perinuclear region of the epithelial cancer cells in both serous and mucinous 
ovarian carcinomas (99%, 439 of 442 and 95%, 53 of 56 respectively). The stromal compartment 
was positive in only 7.9% (35 of 442) of serous, but in 62% (34 of 55) of mucinous cases (Table 
12).  The nonneoplastic ovarian surface epithelium (n=6) was negative or only weakly positive for 
COX-2 immunostaining. Elevated COX-2 immunoreactivity (scores 2-3) in the epithelial carcinoma 
cells clearly differed from the staining pattern of the non-neoplastic surface epithelium and it was 
seen in 70% (310 of 442) of the serous and in 39% (22 of 56) of the mucinous tumors. In serous 
ovarian carcinoma, there was no elevated (scores 2-3) stromal COX-2 expression, but it occurred in 
24% (13 of 55) of mucinous tumors (Table 12).  
 
COX-2 expression was detected in 12 serous and 3 mucinous ovarian cancer specimens by RT-PCR 
and Western blot analysis. Expression of COX-2 mRNA was apparent by RT-PCR in 75% (9 of 12) 
of serous and in 67% (2 of 3) of mucinous ovarian carcinoma specimens. COX-2 protein was 
detected by the Western blot method in 42% (5 of 12) of the serous and in 33% (1 of 3) of the 
mucinous ovarian carcinoma specimens. All tumors that expressed COX-2 protein by Western blot 
were also positive for COX-2 mRNA by RT-PCR.  The expression of COX-2 was investigated also 
in three human serous, OVCAR-3, CaOV-3, and ES-2, and in one mucinous EFO-27 ovarian 
carcinoma cell lines. At the basal level, no COX-2 expression appeared in any of the ovarian 
carcinoma cell lines, but IL-1β did induce COX-2 expression in OVCAR-3 cells. In the CaOV-3 
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cell line, COX-2 was induced with PMA, but not with IL-1β, and the expression was not as strong 
as in the OVCAR-3 cell line. Neither ES-2 nor EFO-27 expressed any detectable basal or inducible 
COX-2. 
 
 
Table 12 . Expression of COX-2 protein in epithelial and in stromal cells of mucinous and serous 
ovarian carcinoma specimens in vivo as detected by immunohistochemistry.  
 
1 Chi-square test between serous and mucinous tumors inside same scores 
2 Not significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
          Epithelial Cox-2 immunopositivity in ovarian carcinomas 
Scores Positive/n (%) Positive/n (%) P-value1 
 Serous Mucinous  
 
1-3 
 
439/442 (99%) 
 
53/56 (95%) 
  
NS2 
2-3 310/442 (70%) 22/56 (39%) < 0.0001 
 
           Stromal Cox-2 immunopositivity in ovarian carcinomas 
Scores Positive/n (%) Positive/n (%) P-value1 
 Serous Mucinous  
 
1-3 
 
35/442 (7.9%) 
 
34/55 (62%) 
 
< 0.0001 
2-3 0/442 (0%) 13/55 (24%) < 0.0001 
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2.2. Correlation of COX-2 expression with clinical parameters 
 
In serous ovarian carcinoma, elevated expression of COX-2 was associated with age over 57 years 
(P=0.0099), high histological grade (P<0.0001), and residual tumor size over 1 cm (P=0.0111). No 
correlation appeared between COX-2 staining intensity and stage, tumor size, lymph-node positivity 
or positive finding of carcinoma cells in ascites. In mucinous ovarian carcinoma, the only 
significant correlation was between epithelial COX-2 expression and high grades (grades 2-3) 
(P=0.0285). Stromal COX-2 expression in serous or mucinous carcinoma showed no correlation 
with any clinical parameters.  
 
 
Table 13. Association of elevated epithelial COX-2 immunoreactivity with clinical parameters in 
serous (n= 442) versus mucinous (n=56) ovarian carcinomas. 
 
Clinical features 
Serous 
COX-2/n (%) P1 
Mucinous 
COX-2/n (%) 
 
P1 
Age:   =0.0099  NS3  
≤ 57/≤ 542 144/223 (65%)  13/29 (45%)  
> 57/>54 2 166/219 (76%)  9/27 (33%)  
Histological grade:  <0.0001  NS  
1 96/166 (58%)  14/44 (32%)  
2 86/114 (75%)  7/11 (64%)  
3 125/156 (80%)  1/1 (100%)  
2-3 211/270 (78%) <0.00014 8/12 (67%) =0.02854 
Stage:  NS   NS  
I 63/90 (70%)  18/44 (41%)  
II 43/61 (70%)  1/2 (50%)  
III 159/237 (67%)  3/9 (33%)  
IV 43/52 (83%)  0/1 (0%)  
II-IV 245/350 (70%) NS 5 4/12 (33%) NS 5 
 
1 Chi-square test 
2 Mean age at diagnosis; 57 years in serous and 54 years in mucinous carcinomas  
3 Not significant 
4 Versus grade 1 
5 Versus stage I 
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2.3. Correlation of COX-2 expression with some biomarkers of ovarian 
carcinoma 
We observed that elevated COX-2 expression occurred more frequently in serous tumors with 
altered (completely negative or increased) p53 staining than in tumors with normal (weak) p53 
immunoreactivity (Table 14). In tumors with altered p53 expression COX-2 expression was also 
elevated in 81% (209/259) of cases and COX-2 was low in 19% (50/259) of cases (p<0.0001). In 
respect to SMAD4, elevated COX-2 expression also appeared more frequently in tumors with 
altered (negative or decreased) SMAD4 staining than in tumors with normal SMAD4 
immunostaining (P=0.0004). Tumors with combined defective expression of p53 and SMAD4 more 
frequently expressed elevated levels of COX-2 than did tumors with only one of the tumor 
suppressor genes showing altered expression (Table 14). Elevated expression of COX-2 occurred 
more frequently in tumors with amplification of the oncogene Her-2/neu than in tumors with 
normal Her-2/neu status (P=0.0479; Table 14). 
In mucinous carcinoma p53, SMAD4, or Her-2/neu alterations are not so frequent than in serous 
ovarian carcinoma. In mucinous tumors p53 was altered in 20% (10/50) of cases and in these 
tumors also COX-2 expression was elevated in 60% (6/10) of cases (not shown). There was no 
correlation between Her-2/neu amplification and elevated COX-2 expression in mucinous tumors. 
However, we observed correlation of stromal COX-2 expression with stromal inhibin-α expression 
(p=0.0058), and there appeared to be colocalization of these two signals. The expression of inhibin-
α had no other associations with any clinical parameters like age, grade, or stage. 
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Table 14. Association of elevated epithelial COX-2 expression with immunostaining for p53 and 
SMAD4, and amplification of Her-2/neu in serous ovarian carcinoma. 
 
Immunostaining n Elevated COX-2/n (%)  P1 
P53:  437  <0.0001 
Normal  96/178 (54%)  
Negative  59/67 (88%)  
Increased  150/192 (78%)  
    
SMAD4:  433  =0.0004 
Normal  184/286 (64%)  
Negative or decreased  119/147 (81%)  
    
Normal p53 and normal SMAD4  76/143 (53%)  
    
Normal p53 and altered SMAD4  18/31 (58%) NS2,3 
    
Altered p53 and normal SMAD4  108/143 (76%) =0.00013 
   NS4 
     
Altered p53 and altered SMAD4  99/114 (87%) <0.00013 
   =0.00134 
   =0.02645 
    
Normal HER-2/neu 323 163/254 (64%) =0.0479 
Amplified HER-2/neu  53/69 (77%)  
    
 
1 Fisher exact test. 
2 Not significant. 
3 Versus normal p53 and normal SMAD4. 
4 Versus normal p53 and altered (negative or decreased) SMAD4. 
5 Versus altered (negative or increased) p53 and normal SMAD4. 
 
 
2.4. Correlation of COX-2 expression with survival  
Of 442 serous ovarian carcinoma patients 244, (55%), and of 56 mucinous ovarian cancer patients 
with a known COX-2 score, 7 (13%) died of ovarian cancer during follow-up. Elevated epithelial 
COX-2 expression was associated with decreased disease-specific survival among serous ovarian 
cancer patients (P=0.0011, Kaplan-Meier). The 5-year survival rate was 60% (95% CI; 51-68%) in 
patients with low COX-2 expression, and was 45% (95% CI; 39-51%) in patients with high COX-2 
expression. When COX-2 expression was divided into three categories (score 0-1, score 2, and 
score 3) probability of survival was progressively lower as category number rose (P=0.0004). No 
correlation appeared between stromal COX-2 expression and survival among serous ovarian cancer 
 51
patients. For mucinous ovarian cancer patients, no significant correlation appeared between 
epithelial or stromal Cox-2 expression and survival (P=0.1417 and P=0.7189, respectively), 
although expression of inhibin-α correlated with better survival (p=0.0394; Kaplan-Meier).  
 
Multivariate analysis to evaluate the independence of COX-2 expression as a prognostic factor in 
serous ovarian carcinoma showed that age (P=0.0134), grade (P<0.0001), stage (P<0.0001), and 
residual tumor size (P<0.0001) were independent prognostic factors, but inclusion of tumor size 
(P=0.8989) or COX-2 expression (P=0.7439) did not add significant independent prognostic 
information. COX-2 was also not an independent prognostic factor inside clinically meaningful 
subgroups (age, grade or stage) in serous ovarian carcinoma. 
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3. HuR EXPRESSION IN SEROUS AND MUCINOUS OVARIAN CARCINOMA 
(III, IV) 
3.1. Expression of HuR protein in serous and mucinous ovarian carcinoma  
Localization and frequency of HuR protein expression in serous and in mucinous ovarian carcinoma 
was similar. Nearly all serous and mucinous ovarian tumors had HuR expression in the nucleus or 
in both the nucleus and the cytoplasm. HuR protein was expressed only in the nucleus of epithelial 
cells in 47% (210/445) of serous and in 53% (30/57) of mucinous ovarian carcinoma samples. 
Cytoplasmic HuR expression was detectable in epithelial cancer cells in 52 % (233 of 445) of 
serous and in 47% (27 of 57) of mucinous ovarian carcinomas. In nonneoplastic stromal cells, HuR 
expression was observed mainly in the nucleus, and cytoplasm was positive in only 3% (15 of 439) 
of serous and in 7% (4 of 56) of mucinous ovarian carcinomas. For statistical analysis we have used 
two categories: ”only nuclear staining” and “cytoplasmic staining” (Table 15). Cytoplasmic HuR 
expression always appeared together with nuclear HuR expression, and no tumors showed only 
cytoplasmic HuR expression. 
 
 
Table 15. Localization of HuR protein expression in serous and mucinous ovarian carcinomas. 
 
HuR Staining Serous Ovarian Carcinoma Mucinous Ovarian Carcinoma 
 
Epithelial (n=445) 
 n (%) 
Stromal (n=439)  
n (%) 
Epithelial (n=57) 
 n (%) 
Stromal (n=56) 
n (%) 
Negative 2 (0.4%) 6 (1.4%) 0 (0%) 0 (0%) 
Only nuclear 210 (47%) 418 (95%) 30 (53%) 52 (93%) 
Cytoplasmic 233 (52%) 15 (3%) 27 (47%) 4 (7%) 
 
 
3.2. Association of HuR expression with COX-2 expression and clinical 
parameters  
Elevated COX-2 expression correlated significantly with cytoplasmic HuR immunoreactivity in 
epithelial cancer cells both in serous (p=0.0045) and in mucinous (p=0.0162) carcinomas (Table 
16). No correlation appeared between elevated stromal COX-2 expression with HuR protein 
expression in serous or mucinous tumors.  
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Table 16. Association of cytoplasmic HuR immunopositivity with elevated epithelial COX-2 
expression in serous (n= 426) and mucinous (n=56) ovarian carcinoma. 
 
 
HuR immunopositivity 
Serous  
Elevated COX-2/n (%) 
 
P-value1 
Mucinous  
Elevated COX-2/n (%) 
 
P-value1 
Cytoplasm negative 131/205 (64%) =0.00452 7/29 (24%) =0.01623 
Cytoplasm positive 169/221 (77%)  15/27 (56%)  
 
1 Chi-square  
2 Cytoplasm-positive compared to cytoplasm-negative in serous tumors 
3 Cytoplasm-positive compared to cytoplasm-negative in mucinous tumors 
 
In serous carcinoma, cytoplasmic HuR expression was associated with high grade (P<0.0001) and 
with residual tumor size over 1 cm (P=0.0028). No significant association existed between 
cytoplasmic HuR expression and age at diagnosis, stage, or tumor size in serous tumors. In 
mucinous ovarian carcinomas, no correlation appeared between cytoplasmic HuR expression and 
any clinical parameters (age, grade, stage). In addition, stromal cytoplasmic HuR expression 
showed  no association with any clinical parameters in serous or in mucinous tumors. 
 
Among the 445 serous ovarian carcinoma patients, cytoplasmic HuR immunoreactivity was 
associated with decreased disease-specific survival (P<0.0001, Kaplan-Meier). Five-year disease-
specific survival in the cytoplasm-negative category was 60% (95% CI, 53–67), and in the 
cytoplasm-positive category 39% (95% CI, 32–46). Thus, cytoplasmic immunopositivity for HuR 
predicted poor outcome in serous ovarian carcinoma patients. No correlation existed between HuR 
expression and survival in mucinous ovarian carcinoma, which may be due to the few deaths among 
our mucinous ovarian cancer patients. 
 
When multivariate survival analysis was made to evaluate the independence of cytoplasmic HuR 
expression as a prognostic factor, inclusion of cytoplasmic HuR expression added no significant 
independent prognostic information, when four independent covariates (age, grade, stage, and 
residual tumor size) were included in the analysis. However, in the multivariate analysis HuR 
expression was an independent prognostic factor among low-stage serous ovarian carcinomas. In 
mucinous carcinomas HuR was not an independent prognostic marker in any subgroup analysis. 
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3.3. Effect of HuR siRNA and LMB on COX-2 expression in ovarian cancer cells  
In order to study the effect of HuR expression in ovarian cancer cells on ARE-containing mRNA 
molecules, we chose to utilize HuR-targeted siRNA molecules to inhibit HuR expression. In 
addition, we used LMB, which inhibits transport of the HuR-protein/COX-2 mRNA complexes 
from the nucleus to the cytoplasm, where the COX-2 protein translation happens (Brennan and 
Steiz 2001, Gallouzi and Steiz 2001, Kau and Silver 2003). OVCAR-3 cells transfected with HuR 
siRNA (200 nM), inhibited expression of HuR and IL-1β-induced COX-2 expression. β-actin 
siRNA, serving as a control, did not reduce expression of either HuR or COX-2. LMB inhibited IL-
1β-induced COX-2 expression in OVCAR-3 cells in a concentration-dependent manner. All this 
suggests that in ovarian cancer cells HuR is necessary for COX-2 expression.  
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DISCUSSION 
 
We investigated the expression and regulation of the inducible prostanoid synthesis enzyme COX-2 
in female reproductive organs. COX-2 expression was studied in pregnant myometrium as a model 
of physiological state and in ovarian carcinoma as a model of pathological state. Regulation of 
COX-2 expression was studied in cultured myometrial smooth muscle cells and in cultured serous 
ovarian carcinoma cell lines.    
 
1. COX-2 IN MYOMETRIAL CELLS IN VIVO AND IN VITRO 
Myometrium is the main target organ of prostanoids during parturition. We observed that the onset 
of labor induced an over 15-fold induction of COX-2 mRNA expression in the myometrium. While 
it had been previously shown that expression of COX-2 transcript is elevated in amnion and 
chorion, induction of COX-2 at these sites had been only 2- to 4-fold (Hirst et al. 1995, Slater et al. 
1995, Fuentes et al. 1996, Mijovic et al. 1997). These data indicate that although myometrial COX-
2 expression is lower than that in the fetal membranes before the onset of labor, it increases 
dramatically during labor, and may thus play an important role in production of prostanoids during 
labor. According to previous studies in human myometrium, Slater et al. (1999) found expression of 
COX-2 mRNA to be elevated before the onset of labor, whereas Zuo et al. (1994) found a decrease, 
and Moore et al. (1999) found no change in expression level of COX-2 mRNA at the onset of labor. 
These discrepancies may depend on the collection of specimens or on different methods used, or 
both. In our material, all women in the in-labor group had received an oxytocin infusion to support 
their contractions. It is, however, unlikely that this oxytocin infusion can explain the induction of 
COX-2 expression in the in-labor samples, because we were unable to show any stimulation of 
COX-2 expression by oxytocin in cultured myometrial cells.  We cannot, however, exclude the 
possibility that the sensitivity of cultured myometrial cells to oxytocin is different from that of 
myometrial cells in vivo, which could depend, for example, on the hormonal milieu in the in vivo 
condition. In contrast to oxytocin, treatment of myometrial cells with proinflammatory cytokines 
induced expression of COX-2. The highest, a 17-fold induction, was achieved by stimulation of 
myometrial cell lines with IL-1β. The effect of IL-1β was not dependent on pregnancy, while an 
identical pattern of COX-2 induction was observed in myometrial cells isolated from the fundal part 
of the uterus from a non-pregnant patient. Previously, cytokines, especially IL-1β, have been shown 
to stimulate the production of prostanoids in cultured human myometrial cells (Abel and Kelley 
 56
1979, Casey et al. 1984, Pollard and Mitchell 1996, Gramatopoulos and Hillhouse 1999). PGI2 was 
the major prostanoid produced in myometrial smooth muscle cells, which is consistent with earlier 
data (Abel and Kelley 1979). Mechanistically this had been linked to activation of PLA2, which 
liberates AA from membrane phospholipids. Our data thus provide an additional mechanism for 
stimulation of myometrial prostanoid production by induction of COX-2 expression.  All this 
indicates that cytokines induce expression of COX-2, which leads to the subsequent increase in 
production of contractive PGs and relaxative PGI2 in fetal membranes and also in myometrium.  
 
In infection-induced premature labor (Romero et al. 1989) and also in normal labor in human 
(Romero et al. 1990), high levels of IL-1β have been detected. In animal models the increased 
release of IL-1β  by mechanical stretch of myometrium has been shown to increase the expression 
of mRNA for COX-2 (Wu et al. 1999), oxytocin receptor (Ou et al. 1998), and connexin43 (Ou et 
al. 1997), all of which are important factors increasing the contractile activity in uterus.  Also in 
human uterus mechanical stretch of myocytes results in increased expression of COX-2 mRNA and 
protein activity (Sooranna et al. 2004). Since cytokines may facilitate their labor-inducing 
properties through induction of COX-2, it is tempting to speculate that inhibition of COX-2 may be 
a useful strategy in preventing premature contractions. Indeed, non-selective inhibitors of the COX-
enzyme, for instance indomethacin, have been used in suppression of preterm contractions, but their 
use is limited due to adverse effects such as closure of the ductus arteriosus, reduced amniotic fluid, 
and elevated risk for necrotizing enterocolitis. Some authors have speculated that the use of COX-2 
selective inhibitors would be an effective means to reduce premature contractions with an 
acceptable side-effect profile (Sawdy et al. 1997). However, according to genetic disruption studies 
in mice, ductus arteriosus patency requires both Cox-1 and -2 enzymes (Loftin et al. 2001). There 
are no studies in which human fetal PG synthesis in ductus arteriosus has been studied. In addition, 
COX-2 enzyme may be important in normal renal function in fetus. This is supported with the case 
study which descibed a possible link between the use of the COX-2 selective inhibitor nimesulide 
and neonatal renal failure (Peruzzi et al. 1999). In another study, nimesulide showed a significant 
benefit in women at high risk for preterm delivery (Sawdy et al. 2004). In that study, no harmful 
side-effects were observed provided that fetal well being was monitored closely with ultrasound.  
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2. COX-2 EXPRESSION IN SEROUS AND MUCINOUS OVARIAN 
CARCINOMA 
Our results provide evidence for COX-2 expression in serous (n=442) and mucinous (n=56) ovarian 
carcinomas. The COX-2 protein expression was observed mainly in the epithelial cancer cells, and 
also in the stromal compartment, but nonneoplastic ovarian surface epithelium was negative or 
weak for COX-2 immunostaining. All samples were taken in primary operations before the patients 
had received any chemotherapy, which was crucial because chemotherapy can induce COX-2 
expression. The tissue microarray technique used in the immunohistochemical part of the study 
proved to be useful, since it enabled the simultaneous staining which made the protocol more 
consistent and reliable.  
 
We found the amount and localization of COX-2 immunopositivity to vary significantly between 
serous and mucinous ovarian carcinomas. COX-2 expression in epithelial cancer cells was elevated 
significantly more often in serous (70%) than in mucinous (39%) tumors (P<0.0001), which is 
consistent with data published by Shigemasa et al. (2003) (34% vs. 17%) and Seo et al. (2004) 
(65% vs. 6%). In addition, there was a striking difference between the expression level in the 
stromal cells, in which COX-2 expression was found significantly more often in mucinous (62%) 
than in serous (7.9%) ovarian carcinomas (p<0.0001). There are no previous studies in which as 
high stromal COX-2 expression as we observed in mucinous tumors has been found in ovarian 
carcinoma, although elevated COX-2 expression has been detected in epithelial cells of ovarian 
carcinoma (Klimp et al. 2001, Matsumoto et al. 2001b, Denkert et al. 2002, Ferrandina et al. 2002a 
and b, Landen et al. 2003, Shigemasa et al. 2003, Ali-Fehmi et al. 2004). These studies have shown 
a relatively high variation in COX-2 positivity (42-89%), which may depend on the use of differing 
antibodies, scoring criteria, and patient selection. Two studies have failed to detect any COX-2 
expression in ovarian carcinoma (Dore et al. 1998, Gupta et al. 2003), which may depend on a 
limited number of ovarian carcinoma specimens in these studies or be due to the use of insensitive 
assays.  
 
In our study, elevated epithelial cancer cell expression of COX-2 in serous ovarian carcinoma was 
associated with reduced survival, and this is in accordance with previous results (Denkert et al. 
2002, Ferrandina et al. 2002a and b, Ali-Fehmi et al. 2003, Seo et al. 2004, Raspollini et al. 2004). 
In the study of Denkert et al. (2002), COX-2 expression was an independent prognostic factor for 
poor survival, which is consistent with findings in esophageal carcinoma (Buskens et al. 2002). We 
were unable, however, to recognize COX-2 as an independent prognostic variable in the current 
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ovarian cancer material, but found instead a highly significant correlation of COX-2 expression 
with high histological grade, which was a strong independent covariate in the multivariate assay. 
Denkert et al. (2002) used a different grading system and included several histological subtypes in 
their material, which may explain the discordance in the findings between their and our material. In 
addition to survival and grade we observed epithelial COX-2 expression to associate with high age 
and large residual tumor size in serous carcinomas, but saw no association with stage, which is 
consistent with several other reports (Matsumoto et al. 2001, Denkert et al. 2002, Ferrandina et al. 
2002a and b, Shigemasa et al. 2003, Li et al. 2004).  Similarly to serous tumors, COX-2 expression 
correlated with high grade in mucinous tumors, but in contrast to serous tumors, we found no 
correlation with the survival of mucinous ovarian cancer patients. This may depend on the few 
deaths among our mucinous ovarian carcinoma patients. 
 
Mucinous ovarian carcinoma is the first type of tumor, in which we have found high stromal 
expression of COX-2 without any evidence for tissue injury. Previously, our research group found 
strong stromal COX-2 expression at sites of erosion, ulceration, and around necrosis in digestive-
tract (Buskens et al. 2002, Saukkonen et al. 2001), urothelial (Ristimäki et al. 2001), and lung 
(Wolff et al. 1998) carcinomas. In the studies by Ferrandina et al. (2002a and b) some stromal 
COX-2 expression was evident in lymphoid cells, but in other studies no stromal COX-2 
immunopositivity appeared in ovarian carcinoma, although mucinous tumors were also included 
(Matsumoto et al. 2001, Shigemasa et al. 2003, Ali-Fehmi et al. 2004). In our study material, 
stromal COX-2 expression in serous or mucinous carcinoma showed no correlation with any 
clinical parameters, although in cervical carcinoma high stromal COX-2 expression correlated with 
better response to neoadjuvant treatment and to longer survival (Ferrandina et al. 2002c, Ferrandina 
et al. 2004). This might be explained by the low amount of stromal COX-2 expression in our serous 
ovarian carcinoma material and the relatively low number of deaths among mucinous carcinoma 
patients. The localization of COX-2 expression in the inhibin-α-positive stromal cells in proximity 
to cancer cells suggests that there may exist a cancer cell-derived paracrine factor that can regulate 
expression of both inhibin-α and COX-2 in the stromal cells. An alternative explanation is that 
expression of inhibin-α  and of COX-2 is directly linked. This hypothesis is supported by the 
observation that prostaglandins can induce inhibin-α expression in human granulosa-luteal cells 
(Erämaa and Ritvos 1996). However, the role and significance of stromal COX-2 expression in 
ovarian carcinogenesis remains unknown.  
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3. HuR EXPRESSION IN SEROUS AND MUCINOUS OVARIAN 
CARCINOMA 
 
 
Increase in nuclear HuR immunoreactivity has been observed in high-grade brain tumors (Nabors et 
al. 2001) and in colorectal carcinomas (Dixon et al. 2001). We were the first, however, to publish 
on cytoplasmic HuR expression as associated with poor outcome in the carcinoma patient 
(Erkinheimo et al. 2003). Thereafter, HuR has been the first mRNA stability protein expression of 
which has been linked to the reduced survival of carcinoma patients. We found that elevated 
cytoplasmic HuR expression was associated with decreased disease-specific survival (P<0.0001), 
high-grade (P<0.0001), and large residual tumor size (P=0.0028) in serous ovarian carcinomas. 
Furthermore, HuR expression was an independent prognostic factor among low-stage serous 
ovarian carcinomas when age, grade, and residual tumor size were included in the multivariate 
analysis. This may indicate that the carcinogenic role of HuR is more important in low-stage 
tumors. In contrast to serous tumors, mucinous ovarian carcinomas shared no correlation between 
HuR expression and clinical parameters, including survival. We also found that COX-2 
immunoreactivity correlated with cytoplasmic HuR expression both in serous (p=0.0045) and in 
mucinous (p=0.0162) carcinomas, but only in the epithelial cancer cells.  
 
After our publication (2003), Denkert et al. showed that cytoplasmic HuR expression is associated 
with elevated COX-2 expression, increased tumor grade, or mitotic activity in ovarian and breast 
carcinoma (Denkert et al. 2004 a and b), and lower survival in ovarian carcinoma (Denkert et al. 
2004a). Overexpression of HuR has been shown to enhance COX-2 expression in colorectal cancer 
cells (Dixon et al. 2001) and inhibition of HuR to reduce COX-2 expression in breast carcinoma 
(Sengupta et al. 2003). We could show that IL-1β-induced COX-2 expression in OVCAR-3 serous 
ovarian carcinoma cells was inhibited by HuR siRNA and by LMB.  Since LMB can inhibit 
nucleocytoplasmic transport of HuR protein (Kau et al. 2003) and HuR siRNAs were shown to 
reduce expression of HuR, our data indicate that there exists a direct link between HuR expression 
and COX-2 expression in ovarian carcinoma. All this indicates that cytoplasmic expression of HuR 
is predominantly a property of transformed epithelial cells in ovarian carcinoma, in which it can 
directly regulate COX-2 expression. Thus, induction of COX-2 expression may be part of the 
machinery that promotes HuR-induced carcinogenesis. 
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4. FUTURE PROSPECTS 
 
The synthesis of PGs is induced during spontaneous labor, and the PGE2 derivatives are used as 
effective drugs to induce labor in cases with maternal or fetal problems or prolonged pregnancy. In 
addition, nonselective inhibitors of the COX enzyme have been used in suppression of preterm 
contractions, although their use is limited due to fetal adverse effects. According to many studies on 
COX-2 expression in fetal membranes and myometrium, COX-2 activity is crucial in the synthesis 
of PGs during pregnancy and parturition. The COX-2 enzyme is responsible for the inducible 
synthesis of PGs which is needed during parturition. Thereafter, the inhibition of COX-2 activity 
would be an effective means to suppress preterm production of PGs and contractions. However, 
according to animal and human studies, COX-2 selective inhibitors may lead to renal and ductal 
side-effects as do nonselective inhibitors. Selective COX-2 inhibitors therefore cannot be 
recommended for routine use in prevention of premature labor, but randomized placebo-controlled 
trials are required to assess the usefulness of COX-2 selective inhibitors in this condition. These 
studies should be performed in centers that can provide sufficient ultrasound follow-up of the 
patient. 
    
The main determinants of treatment options in ovarian carcinoma are stage  
and grade. However, the biological behavior, response to available treatment, and outcome vary 
greatly inside the same stage and grade categories. Therefore it may be suggested that ovarian 
carcinoma constitutes a number of distinct subgroups whose optimal treatment should also differ. 
Thus far, none of the biological markers, including p53, has been strong enough for prognosis of 
ovarian carcinoma in the clinical use. It is therefore important to seek novel biological markers 
which could classify ovarian carcinomas more precisely.  In our material, COX-2 expression was 
not an independent prognostic factor. COX-2 expression status alone is thus not a strong enough 
marker to classify ovarian tumors into subgroups. However, epidemiological and experimental data 
support the use of NSAIDs and selective COX-2 inhibitors as chemopreventive agents in a number 
of malignancies, including colorectal, breast, esophageal, and lung carcinomas. Evidence also exists 
that regular, long-term use of ASA or other NSAIDs is inversely associated with ovarian cancer 
incidence (Akhmedkhanov et al. 2001, Sorensen et al. 2003). Since we and others have observed 
that elevated COX-2 expression is associated with reduced survival in serous ovarian cancer, and 
COX-2 inhibitors can modulate tumor growth and metastasis, it is theoretically possible that COX-2 
inhibitors would be beneficial in treatment of ovarian cancer. According to the Adenomatous Polyp 
Prevention on Vioxx (APPROVe) study, blood pressure was elevated in patients in the rofecoxib 
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group early in the course of the study and the incidence of myocardial infarction and thrombotic 
stroke was significantly increased after a year of treatment, results which are in accordance with 
those of the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial (Merck, Bombardier et al. 
2000). These results may reduce the enthusiasm to use selective inhibitors in chemoprevention, but 
may not have a great impact on the possibility of using COX-2 inhibitors in a neoadjuvant or 
adjuvant setting. However, clinical trials with selective COX-2 inhibitors are necessary in order to 
understand the role and observe the safety of these drugs in the treatment of ovarian carcinoma.  
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